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SUMMARY
In myocardial ischemia, arrhythmias due to excessive norepinephrine 
(NE) release can cause cardiac dysfunction and sudden cardiac death. 
Therefore, it is essential to understand how endogenous mediators can 
influence NE release from cardiac sympathetic nerves (cSNE).
This work primarily focuses on angiotensin II (ANG II), a positive 
modulator of NE release which is elevated in the ischemic heart. The origin of 
cardiac renin, the pivotal enzyme in the formation of ANG II, was investigated 
using renin-specific antibodies. These studies are the first to demonstrate 
that mast cells are a source of cardiac renin. This observation was extended 
to the human mast cell line HMC-1. Mast cell degranulation was found to 
release active renin which promotes NE release from cSNE via the formation 
of ANG II. Accordingly, a positive coupling was established between ATi- 
receptor activation and the trigger for carrier-mediated NE release, the 
neuronal NaVH" exchanger (NHE). Ischemia-reperfusion studies in ex vivo 
hearts from guinea pigs and mast cell-deficient mice confirmed that mast-cell- 
derived renin has the capacity to trigger the cardiac renin-angiotensin 
cascade, leading to local ANG II formation, enhanced carrier-mediated NE 
release and arrhythmic cardiac dysfunction.
Cardiac histamine inhibits NE release via activation of Hs-receptors 
located on cSNE. The signal transduction mechanisms responsible for H3- 
receptor-mediated attenuation of exocytotic NE release were studied in an H3 - 
transfected neuroblastoma cell line. H3-receptor activation was found to 
ultimately result in attenuated protein kinase A (PKA) activity, which
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decreases Ca^  ^ influx through voltage-gated channels and consequently 
diminishes NE exocytosis.
These studies have revealed a paradoxical role of mast cells as a 
source of both cardiac renin and histamine. Acting via A T r and Hs-receptors, 
respectively, ANG II and histamine have counteracting roles in the modulation 
of NE release from cSNE. Since minimizing NE release is protective in 
myocardial ischemia, novel therapeutic strategies should be directed towards 
inhibition of the cardiac renin-angiotensin system whilst simultaneously 
exploiting Hs-receptor signaling mechanisms.
Ill
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1. introduction
1.1 Norepinephrine: A Sympathetic Neurotransmitter
The autonomic branch of the peripheral nervous system is responsible 
for controlling involuntary regulation of organ function and homeostasis. 
Based on anatomical and functional differences, this branch of the nervous 
system is further subdivided into the sympathetic and parasympathetic 
systems, von Euler was awarded the Nobel Prize in 1970 for proving that the 
catecholamine norepinephrine (NE), shown in Figure 1.1, is the principal
neurotransmitter of the sympathetic nervous system
OH
HO
Parasympathetic responses conserve energy
tending to dominate when one is in a resting state.
Figure 1.1 The . .. .. .
c h e m i c a l  s t r u c t u r e  o f  '"hei-eas sympathetic responses are geared
norepinephrine
towards preparing the body for the 'fight-or-flight 
response, i.e., directing more oxygen and glucose toward the brain, heart and 
skeletal muscle, the organs most active in responding to stress. Hence,
release of NE and epinephrine causes increased heart rate, blood pressure 
and cardiac output, diversion of blood flow from the skin and splanchnic 
vessels to those supplying skeletal muscle and the brain, increased pupil size, 
increased breathing rate and bronchiolar dilation, mobilization of glucose from 
fat and glycogen stores in the liver, and slowing of digestive activity (Rang et 
al., 1998; Goldstein, 1995; Tellioglu and Robertson, 2001). NE also has 
functions in the central nervous system, regulating mood, sleep, behavioral 
state, and degree of alertness and arousal (Ressler and Nemeroff, 2000; 
Mallick et al., 2002).
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NE biosynthesis begins with active uptake of the circulating amino acid 
tyrosine into sympathetic neurons (Nagatsu et al., 1964). Within the neuronal 
cytoplasm, tyrosine becomes hydroxylated by tyrosine hydroxylase to form 3,
4-dihydroxyphenylalanine (DOPA). This is the rate-limiting step in the 
synthesis of NE, requiring oxygen, iron and tetrahydrobiopterin as cofactors 
(Levitt et al., 1965). Tyrosine hydroxylase is subject to feedback inhibition by 
increased intracellular catecholamine levels, with its activity being restored 
upon catechol release from secretory granules (Nagutsu et al., 1964). 
Aromatic L-amino acid decarboxylase catalyzes the rapid conversion of 
DOPA to dopamine. At sites of NE neurotransmission, dopamine is 
transported to synaptic vesicles and via hydroxylation, copper-containing 
dopamine (3-hydroxylase generates NE (Kaufman and Friedman, 1965). 
Vesicular NE becomes complexed with ATP, calcium and chromogranin A 
(Fried, 1980). Newly synthesized NE can also be methylated to form 
epinephrine by phenylethanolamine-N-methyltransferase (PNMT) (Axelrod, 
1966): this however is localized to the cytoplasm of adrenomedullary 
chromaffin cells and to some regions of the central nervous system, and 
epinephrine then gets stored in a different subset of vesicles.
Figure 1.2 summarizes the events that occur at a noradrenergic 
junction. Under physiological conditions, exocytotic release of neuronal NE 
into the synaptic cleft is triggered by the arrival of an action potential, 
depolarization and consequent Ca^ "" influx. The fates of released NE are 
numerous: interaction with post-junctional adrenergic receptors (Section 1.2); 
interaction with auto-inhibitory pre-junctional receptors; pre-junctional re­
uptake via uptake-1 into the nerve; post-junctional uptake via uptake-2 into
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non-neuronal cells; or diffusion into the general circulation. The predominant 
mechanism responsible for terminating the action of NE is re-uptake into the 
nerve via uptake-1 (Iversen, 1973). NE is removed from the synaptic cleft to 
the neuronal cytoplasm, and much of this ‘free’ pool is then recycled into 
synaptic vesicles. There are two main catecholamine-metabolizing enzymes, 
monoamine oxidase (MAO) and catechol-O-methyl transferase (GOMT), both 
located intracellularly. MAO deaminates free NE in the cytoplasm of nerves 
that has been displaced or spilled from synaptic vesicles, or excess NE that 
has been taken in via uptake-1, forming the corresponding aldehyde. 
Subsequently, the carboxylic acid 3, 4-dihydroxymandelic acid (DHMA) is 
rapidly formed by aldehyde dehydrogenase. GOMT catalyzes 0-methylation 
of NE that has diffused into tissues forming normetanephrine. The main 
metabolite of NE excreted in plasma and urine is vanillylmandelic acid (VMA), 
generated by the action of GOMT and MAO on DHMA and normetanephrine, 
respectively (Boulton and Eisenhofer, 1998).
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Tyrosine
TH
DOPA
Sympathetic Nerve 
\  Ending
Vesicles
AAAD
Dopamine
DH
MAO
Dihydroxyphenylglycol
NE
é  VMAT.e -
NET
To Plasma
Presynaptic membrane
Normetanephrine
Postsynaptic membrane
COMT
Figure 1.2 Schematic overview of noradrenergic neurotransmission.
Abbreviations: AAAH, aromatic amino acid decarboxylase; COMT, catechol- 
O-methyl transferase; DH, dopamine p-hydroxylase; DOPA, L-3,4- 
dihydroxyphenylalanine; MAO, monoamine oxidase; NET, norepinephrine 
transporter; TH, tyrosine hydroxylase; VMAT2 , vesicular monoamine 
transporter.
1.2 Adrenoceptors
Catecholamines mediate their physiological and metabolic effects 
throughout the body via membrane-bound receptors called adrenoceptors. In 
1910, Dale observed two distinct effects of epinephrine in isolated vascular 
beds. In general, epinephrine caused vasoconstriction and hence a rise in 
arterial pressure. However, in certain vascular beds vasodilation would occur. 
Furthermore, the vasoconstrictor effect of epinephrine seen in the majority of 
vascular beds could be reversed into vasodilatation by ergotoxine (Barger and
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Dale, 1910). At the time. Dale did not interpret these findings as evidence for 
different adrenoceptor classes. Ahlquist (1948) was the first to clearly 
demonstrate this by studying the relative potencies of five sympathetic amines 
in vasculature, heart, uterus, and intestine. In general, two general orders of 
potency were seen, for most excitatory events e.g. vasoconstriction and 
contraction of the uterus and spleen: NE > epinephrine (E) > isoprenaline 
(Iso); and for most inhibitory events e.g. vasodilatation and relaxation of 
respiratory smooth muscle: Iso > E > NE. This was suggestive of two 
receptor populations which Ahlquist designated a  and p, respectively 
(Ahlquist, 1948).
Since these early observations, the development of more specific 
adrenoceptor ligands, together with advances in molecular techniques has led 
to the discovery of at least 10 different adrenoceptors (Alexander et al., 2001). 
All the adrenoceptors share the same general structure having seven 
membrane-spanning domains, a glycosylated extracellular amino terminus 
and a long intracellular carboxy-terminal polypeptide chain with several 
potential regulatory phosphorylation sites (Raymond et al., 1990). Located 
throughout the body on neuronal and non-neuronal tissues, adrenoceptors 
mediate a diverse range of responses. Some of the main peripheral actions 
of NE and epinephrine are summarized in Table 1.1.
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Receptor Agonists Antagonists Tissue Responses
(«■lA, IB, 1d )
E > NE » ls o  
Phenylephrine 
Cirazoline 
Methoxamine
Prazosin
Corynanthine
Vascular & 
Genitourinary 
smooth muscle
Liver
Intestinal 
smooth muscle
Heart
Contraction
Glycogenolysis
Gluconeogenesis
Hyperpolarisation
Relaxation
Increased 
contractile force 
Arrhythmia
a .
. (0 t2 A ,2 B ,2 c )
NE >E » ls o  
Clonidine 
UK 14,304
Yohimbine
Rauwolscine
Pancreatic 
islets (p-cells)
Platelets
Nerve terminals
Vascular 
smooth muscle
Decreased 
insulin secretion
Aggregation
Decreased NE 
release
Contraction
Pi
Iso > E = NE 
Dobutamine
Atenolol 
CGP 20712A
Heart Increased force 
and rate of 
contraction
P2
Iso > E » N E
Terbutaline
Salbutamol
ICI 118,551 Smooth muscle
(vascular,
bronchial,
gastrointestinal,
genitourinary)
Skeletal muscle
Relaxation
Glycogenolysis 
Uptake of
Ps Iso = NE > E BRL 37344 SR59230A Adipose tissue Lipolysis
P4
Low affinity 
for NE and E 
No selective
No selective, 
bupranolol > 
CGP20712A
Heart Increased force 
and rate of 
contraction
Table 1.1 Actions of catecholamines at peripheral adrenoceptors
(Robinson and Hudson, 2000; Rang et al., 1998) Abbreviations: E, 
epinephrine; Iso, isoprenaline.
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1.3 Myocardial Ischemia and Norepinephrine Release
In ischemic conditions, when the heart is depleted of both oxygen and 
glucose due to reduced blood flow, not only is there an increased efflux of 
catecholamines into the general circulation, but there is also enhanced 
sympathetic nerve activity to the heart (Schomig et al., 1995). Acting via 
postsynaptic a r  and Pi-adrenoceptors, NE increases peripheral vascular 
resistance and cardiac output, respectively, thus exacerbating the primary 
ischemia. Moreover, az-adrenoceptor-mediated platelet activation and 
aggregation could ultimately cause a coronary occlusion resulting in 
myocardial infarction (an area of cardiac necrosis), the extent of which would 
depend upon the duration of ischemia. Ca '^" overload of myocytes, 
pacemaker cells and conducting tissue due to increased IP3 production and 
Ca^ '^  influx, arises as a consequence of a,- and p-adrenoceptor stimulation, 
respectively. This results in uncoordinated myocyte contraction and 
dysrhythmia (Schomig et al., 1991). Hence, a strong correlation exists 
between excessive NE release and the incidence of severe arrhythmias, 
cardiac dysfunction and sudden cardiac death (Schomig et al., 1995; 
Airaksinen, 1999).
There are two main mechanisms of NE release from sympathetic nerve 
endings. Ca^'^-dependent exocytosis prevails under physiological conditions 
and in short periods of myocardial ischemia, whereas protracted myocardial 
ischemia triggers a significantly greater release of NE that is “carrier- 
mediated” and Ca^"-independent. Carrier-mediated NE release occurs due to 
a reversal of the NE transporter, normally responsible for the re-uptake of
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neuronal NE (uptake-1). It is this massive carrier-mediated efflux of NE that is 
responsible for triggering severe arrhythmias (Schomig et al., 1991). During 
protracted myocardial ischemia deprivation of O2 causes sympathetic nerve 
endings to switch from aerobic respiration to anaerobic glycolysis, thus 
leading to ATP depletion and intracellular pH (pHj) reduction. Consequently, 
the ATP-dependent vesicular storage of NE fails and free axoplasmic NE 
accumulates (Kübler and Strasser, 1994).
The pivotal trigger for carrier-mediated release of the free NE is entry 
of Na^ in exchange for axoplasmic H  ^ via the NaVH"" exchanger (NHE) 
(Schomig, 1990; Imamura et al., 1996; Hatta et al., 1997; Kurz et al., 1995). 
NHE activation occurs as a compensatory mechanism to neutralize the 
reduced axoplasmic pH. The NE transporter is Na^- and Cl'-dependent with 
three binding sites, once Na"", Cl" and NE bind, carrier-mediated NE release 
proceeds. With all three of its binding sites vacant the NE transporter is freely 
mobile, however, upon binding Na'" this mobility is lost. As Na"” accumulates 
in the axoplasm this increases the availability of the NE transporter to the 
inside of the axonal membrane and enhances the affinity of the free 
axoplasmic NE for the carrier (Sammet and Graefe, 1979). With all three 
binding sites of the NE transporter occupied, carrier-mediated NE release 
proceeds.
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Na%K^-ATPase
ATP
SNE
Ca"-ATPase 
Ca'+
— ► Na^ATPase
NE
NHE
VMAT
Na
EIPA
NE
MAO
DO PEG
DMI
NEdiffusion
ATPAO
cAMP
— «► ARR
myocvles
pacemaker cells /  
conducting tissue
Figure 1.3. Carrier-mediated NE release from a cardiac sympathetic 
nerve ending in protracted myocardial ischemia. (Levi and Smith, 2000b) 
Abbreviations: ARR, arrhythmias; DMI, an inhibitor of the NE transporter; 
EIPA, an inhibitor of the NaVH" exchanger; NHE, NaVh^ exchanger; SNE, 
sympathetic nerve ending; VMAT, vesicular monoamine transporter.
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There are several distinct features that characterize the mechanism by 
which NE is released from sympathetic nerves, as shown in Figure 1.4. NE 
overflow associated with carrier-mediated release is 100 to 1000 times higher 
than that associated with exocytosis. Exocytosis is Ca^^-dependent, being 
attenuated by N-type Ca^^-channel inhibitors e.g. co-conotoxin, and 
potentiated by NE transporter blockers (Imamura et al., 1994). In contrast, 
carrier-mediated NE release is Ca^^-independent and attenuated by both 
inhibitors of the NE transporter and NHE e.g. desipramine (DMI) and ethyl 
isopropyl amiloride (EIPA), respectively (Imamura et al., 1996).
0 10 20 30 40
Time (min)
10-min
schemia
0)-CTXControl DM
e ion.
800
c  600
0 30 40
Time (min)
20-mm
Ischemia
pre­
ischemia
Control DMI EIPA
Reperfusion
Figure 1.4 NE overflow from isolated guinea pig hearts subjected to 10 
min (A) and 20 min (B) global ischemia followed by 45 min reperfusion.
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1.4 Modulation of Norepinephrine Release
Cardiac sympathetic nerve endings possess a variety of cell-surface 
receptors. In myocardial ischemia numerous mediators, including NE are 
released/formed in the proximity of sympathetic nerve endings. Our 
laboratory is particularly interested in the role of these endogenous mediators, 
acting via specific receptors, at modulating NE release. Both negative (e.g. 
histamine, adenosine) and positive (e.g. bradykinin, and angiotensin (ANG)) 
modulators of exocytotic and carrier-mediated NE release in myocardial 
ischemia have been characterized (Imamura et al., 1994; Maruyama et al., 
1999; Hatta et al., 1999; Imamura etal., 1996; Hatta et al., 1997).
1.5 Cardiac Histamine
Histamine is a biogenic amine synthesized by the decarboxylation of 
the amino acid histidine (Metcalfe et al., 1997). In the heart, histamine is 
almost exclusively localized in mast cells (Patella et al., 1995). Histamine is 
released from mast cells upon degranulation, an event triggered by numerous 
immunological and non-immunological stimuli (Patella et al., 1995; Sperr et 
al., 1994). Three of the four known histamine-receptor subtypes are known to 
mediate effects in heart: Hi, H2 and H3 (Hill et al., 1997; Levi and Smith, 
2000), the K d ’s  of which are 160 nM, 1 pM and 40 nM for histamine, 
respectively (Malinowska et al., 1998). Consequently, the amount of 
histamine released determines the cardiac response. For instance, massive 
histamine release associated with acute hypersensitivity reactions induces H2- 
mediated cardiac dysfunction and severe arrhythmias (Levi, 1988; Wolff and
11
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Levi, 1986), whereas moderate histamine release as occurs in ischemia 
evokes Hs-mediated anti-arrhythmic effects (Levi and Smith, 2000b).
Histamine H3 Receptor
Histamine Hs-receptors were discovered by Schwartz and colleagues 
as inhibitory autoreceptors in central histaminergic pathways (Arrang et al., 
1983). Hs-receptors have since also been identified as being inhibitory 
heteroreceptors in cardiac sympathetic nerve endings (Endou et al., 1994; 
Imamura et al., 1994; Imamura et al., 1995). Cardiac nerve endings are 
known to be in close proximity to mast cells which degranulate rapidly with 
ischemia (Frangogiannis et al., 2002), so the endogenous ligand of Hs- 
receptors on cardiac nerve endings is likely to be histamine. The Hs-receptor 
is a G-protein-coupled receptor, thought to be Gj/o linked. In models of short­
lived and protracted myocardial ischemia Hs-receptor activation decreases 
both exocytotic (Imamura et al., 1994) and carrier-mediated NE release 
(Imamura et al., 1996; Hatta et al., 1997) via independent mechanisms. 
Human, rat and guinea pig Hs-receptors have been cloned (Lovenberg et al., 
1999; Lovenberg et al., 2000; Tardivel-Lacombe et al., 2000) enabling the 
stable transfection of SH-SY5Y neuroblastoma cells, a useful simplified model 
of sympathetic nerve endings (Vaughan et al., 1995). Using this cell model, 
Hs-receptor activation has been shown to be coupled to a decrease in NHE 
activity (Silver et al., 2001) hence the subsequent reduction in carrier- 
mediated NE release. In contrast, Hs-receptor-mediated attenuation of 
exocytotic NE release is associated with a reduction in intracellular Ca^ ,^ 
probably as a consequence of decreased Ca^  ^ influx (Silver et al., 2002). 
Recently, our laboratory has demonstrated that hearts from mice lacking Hs-
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receptors release much more NE and develop arrythmias of greater severity 
when subjected to ischemia-reperfusion than congenic control hearts 
(Koyama et al., 2003a; Koyama et al., 2003b). Hence, Hs-receptor agonists 
have potential as novel therapeutic agents in the treatment of myocardial 
ischemia (Mackins and Levi, 2000).
Of particular interest in our laboratory, is the role of angiotensin II 
acting via angiotensin ATi-receptors located on cardiac sympathetic nerve 
endings (cSNE), in the modulation of carrier-mediated NE release.
1.6 The Renin-Angiotensin System 
History
In 1898, Tigerstedt and Bergman demonstrated that intravenous 
injection of renal extracts raised blood pressure; they proposed that a protein 
which they named ‘renin’ was responsible. The concept was also put forward 
that renin released from the kidney mediates its effects as a blood-borne 
chemical messenger (Tigerstedt and Bergman, 1898). Experiments inducing 
hypertension in the dog by partially constricting the renal artery (Goldblatt et 
al., 1934) ultimately led to the successful extraction and partial purification of 
kidney renin (Pickering and Prinzmetal, 1938). Soon after, it was recognized 
that renin was not directly responsible for its pressor effect, and that renin is 
actually an enzyme that forms the vasoactive substance now known as 
angiotensin II (ANG II) (Page and Helmer, 1940; Braun-Menendez et al., 
1940).
13
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Figure 1.5 Summary of the classical renin-angiotensin system.
Classically, the renin-angiotensin system is considered a circulating 
system responsible for regulating blood pressure and body fluid homeostasis. 
The aspartyl protease, renin, secreted by the juxtaglomerular cells of the 
kidney is the key enzyme in the renin-angiotensin system cascade (Figure 
1.5), responsible for cleaving liver-derived angiotensinogen to form the 
decapeptide angiotensin I (ANG I). Angiotensin-converting enzyme (ACE) in 
the lungs, converts ANG I to the main effector of the renin-angiotensin 
system, the highly active octapeptide ANG II. More recently, evidence 
suggests that ANG I and ANG II can also be produced locally at tissue sites. 
All components of the renin-angiotensin system have been demonstrated in 
numerous organs such as the adrenal gland (Wang et al., 2002), pancreas 
(Leung and Chappell, 2003), brain (Culman et al., 2002), ovary (Yoshimura, 
1997), testis (Leung and Sernia, 2003), blood vessels, as well as the heart 
(Danser, 1996; Danser et al., 1999; Dostal and Baker, 1999).
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Angiotensin Receptors
The physiological actions of ANG II are mediated via two major 
subtypes of mammalian ANG II receptor; ATi and AT2 , summarized in Table
2. The ATi receptor is responsible for mediating most of the well known ANG 
ll-mediated physiological effects such as vasoconstriction, enhancement of 
sympathetic activity, aldosterone secretion, thirst, natriuresis and cell 
proliferation, whereas the AT2 receptor tends to oppose ATi-mediated effects. 
Both receptors are cell surface G-protein-coupled (Figure 1.6), but their 
intracellular signaling mechanisms are different.
#3\
Extfaoeilular
Membrane
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m)@©cooH359
Figure 1.6 The mammalian angiotensin ATi-receptor (De Gasparo et al., 
2000)
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A T i
Localization Widely distributed throughout 
cardiovascular, renal, 
endocrine and nervous 
system
Detectable in pancreas, 
heart, kidney, adrenals, brain 
and vasculature
Specific
Antagonists
Biphenylimidazoles e.g. 
losartan
Tetrahydroimidazopyridines 
e.g. PD123319
Physiological
Effects
Vasoconstriction 
Cell proliferation 
Cell hypertrophy 
Antinatriuresis; sodium 
retention
Hormone secretion e.g. 
aldosterone 
Neuronal activation 
Superoxide production 
Endothelin release 
Lipid peroxidation
Vasodilation 
Growth inhibition 
Apoptosis 
Natriuresis
Tissue development and 
repair
NO production
Signaling
Mechanisms
Coupling; Gq, Gi 
t PLC, Î  PLAz, Î  PLD, 
[AC, fCa^^ influx (L- 
type), MAP/JAK/STAT 
pathway
Coupling; Gj? 
t phosphatase activation, 
channel activity, 
j  Ca^" influx (T-type), 
tNO/cGMP, tPLA:
Table 1.2 Summary of angiotensin ATi and AT: receptors. (Berry et al., 
2001; De Gasparo et al., 2000; Stroth and Unger, 1999)
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Cardiac Renin-Angiotensin System 
History
A link between the renin-angiotensin system and cardiac function was 
first noted in 1965 (Koch-Weser, 1965) and became clearer during the 1980s 
(Baker and Khosla, 1986; Jin et al., 1988). Indeed, the development of ACE 
inhibitors such as captopril (Heel et al., 1980) was fundamental in establishing 
the concept of a cardiac renin-angiotensin system. In patients with 
cardiovascular disease, pharmacological inhibition of ACE and/or A T r  
receptors exerts beneficial effects that are at least partly independent of their 
blood pressure-lowering vasodilator effect (Varagic and Frohlich, 2002; 
Burnier and Brunner, 2000).
By definition, a local renin-angiotensin system requires in-situ synthesis 
of all the components required for ANG II production (i.e. renin, 
angiotensinogen and ACE). All renin-angiotensin system components are 
present in cardiac tissue (Danser et al., 1999), although the concept remains 
controversial since the presence of renin-angiotensin system components 
does not necessarily mean that they are synthesized in the heart. Renin 
mRNA and protein has been detected in cardiac atria and ventricles, but the 
source of this myocardial renin is debated. Many investigators still support 
the more traditional concept that all renin is derived from the kidney, and that 
renin present in the heart has been sequestered from the circulation. Indeed 
there is evidence that renin has a high binding capacity in the heart (Danser et 
al., 1997). Cardiac renin has also been shown to disappear after bilateral 
nephrectomy (Von Lutterotti et al., 1994). However, it is possible that a
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cardiac renin-angiotensin system may only become important under 
pathophysiological conditions.
Angiotensinogen is synthesized in all parts of the heart and in cultured 
cardiac myocytes and fibroblasts (Campbell and Habener, 1986; Dostal et al., 
1992). Membrane-bound ACE has been shown to have a non-uniform 
distribution in cardiac tissues, with higher concentrations in valves, atria, 
coronary arteries and ventricles (Yamada et al., 1991). It has been 
demonstrated that most ANG I found in the heart is synthesized in situ, and 
that most cardiac ANG II is generated from in s/fu-synthesized rather than 
circulation-derived ANG I (Van Kats et al., 1998; Muller et al., 1998). 
Consequently, local ANG II concentrations could exceed plasma levels and 
since ANG II receptors of both subtypes ATi and AT: are expressed in the 
heart (Allen et al., 2000), may play important roles influencing cardiac function 
(Dzau, 1987). Indeed, ANG II acting both directly via ATi-receptors and 
indirectly by enhancement of local sympathetic activity is known to mediate 
numerous cardiac effects including increased contractility, arrhythmia, fibrosis, 
cardiac hypertrophy and remodeling (Varagic and Frohlich, 2002; Booz et al., 
2002; Bader, 2002; Lindpaintner and Ganten, 1991).
Newly emerging components
In 2000, angiotensin-converting enzyme 2 (ACE2) was discovered in 
the heart, kidneys and testes (Donoghue et al., 2000). Unlike ACE which 
converts ANG I to ANG II, ACE2 hydrolyzes ANG I to ANG (1-9) and ANG II 
to ANG (1-7) (Vickers et al., 2002). Therefore, ACE2 essentially acts as an 
inhibitor of ANG II formation. In fact, studies in AGE and/or ACE2 knockout
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mice reveal that ACE2 is an essential regulator of heart function (Crackower 
et al., 2002).
Formed by ACE2, ANG (1-7) is gaining recognition as a major 
biologically active product of the renin-angiotensin system (Santos et al., 
2000). Found in the circulation, heart, blood vessels and kidney, ANG (1-7) 
generally opposes ANG ll-mediated actions, such as vasoconstriction and 
proliferation (Carey and Siragy, 2003). Given its counter-regulatory role in the 
renin-angiotensin system, and with evidence of an ANG (1-7) receptor 
referred to as Mas, ANG (1-7) represents a novel target for the development 
of new cardiovascular therapies (Santos et al., 2003; Santos et al., 2005).
Figure 1.7 summarizes the current understanding of the cardiac renin- 
angiotensin system.
19
Thesis Christina J. Mackins
Angiotensinogen
R e n i n  (rate-limltlng)
Non-renin
(cathepsin) ANG INon-ACE
(chymase) / PEP. NEPACE2
ACE ANG (1-9)
ACE, NEP
ANG ANG (1-7)ACE2, PCP, PEP
Inactive
metabolites
MasAT,
Receptors
Figure 1.7 The cardiac renin-angiotensin system -  an overview of 
current understanding. Abbreviations: NEP, neutral endopeptidase; PEP, 
prolylendopeptidase; PCP, prolylcarboxypeptidase.
Angiotensin II, NE Release and Cardiac Arrhythmias
It is well known that ANG II enhances peripheral sympathetic 
neurotransmission (Zimmerman, 1962). Our laboratory has identified pre­
junctional ATi.receptors on cSNE (Seyedi et al., 1997). Recent studies 
suggest that ATrreceptors on cSNE are likely to be stimulated by locally 
synthesized, rather than circulation-derived ANG II. For example, 
sympathetic coronary vasoconstriction is attenuated by reducing local ANG II 
formation, without involving circulating ANG II (Saino et al., 2000). Also, local
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infusion of ANG II to a population of right atrial neurons causes an increased 
release of NE into the interstitial fluid of the dog heart (Farrell et al., 2001).
As mentioned in Section 1.3, protracted myocardial ischemia is 
characterized by massive carrier-mediated NE release from cSNE, triggered 
by activation of the NHE in response to intraneuronal acidosis (Levi and 
Smith, 2000). Since ANG II is known to increase in the ischemic myocardium 
(Jalowy et al., 1999) and it is also a potent stimulator of the NHE (Karmazyn 
et al., 1999; Gunasegaram et al., 1999), it seems likely that endogenous ANG 
II contributes to the carrier-mediated NE release associated with myocardial 
ischemia. In support of this, our laboratory has demonstrated in both animal 
and human models of myocardial ischemia, that ATi-receptor blockade 
reduces carrier-mediated NE release and associated ventricular arrhythmia 
(Maruyama et al., 1999; Maruyama et al., 2000). It has been suggested that 
atrial fibrillation in humans is also linked to activation of a cardiac renin- 
angiotensin system (Goette et al., 2000).
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1.7 Aims
In myocardial ischemia, arrhythmias due to excessive NE release can 
cause cardiac dysfunction and sudden cardiac death. Therefore, the ultimate 
goal of this thesis research is to advance current understanding of the 
mechanisms by which endogenous mediators can influence NE release from 
cSNE. These studies focus on two mediators with opposing modulatory 
actions:
Angiotensin II: The origin of cardiac renin, the pivotal enzyme in the 
formation of ANG II, will be investigated. Also, whether local ANG II can 
promote carrier-mediated NE release from cSNE via a positive coupling 
between ATi-receptor activation and the neuronal NHE will be ascertained. 
Hypothesis: In myocardial ischemia, activation of the renin-angiotensin
cascade leads to local ANG II formation, enhanced carrier-mediated NE 
release and arrhythmic cardiac dysfunction.
Histamine: The signaling pathways implicated in histamine H3-
receptor-mediated attenuation of NE exocytosis will be investigated in a 
neuroblastoma cell line stably expressing the Hs-receptor. Hypothesis: In 
myocardial ischemia, histamine H3-receptor-mediated attenuation of NE 
exocytosis is mediated by a decreased cAMP-dependent phosphorylation of 
voltage-gated channels, which results in diminished influx of Ca^*.
Since minimizing NE release is protective in myocardial ischemia, 
validation of these hypotheses may give rise to potential therapeutic 
strategies.
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2. Characterization of a new source of cardiac renin
2.1 Introduction
In myocardial ischemia, excessive carrier-mediated NE release is 
triggered by activation of the NHE on cSNE (Schomig, 1990). ANG II is a 
potent stimulator of the NHE (Gunasegaram et al., 1999; Karmazyn et al., 
1999) and augments NE release from cSNE via activation of ATi-receptors. 
Our laboratory has previously shown that ATi-receptor blockade in an isolated 
guinea pig heart ischemia/reperfusion model reduces NE release and the 
severity of associated arrhythmias (Maruyama et al., 1999).
A cardiac renin-angiotensin system is known to exist (Dostal and 
Baker, 1999) and ANG II formation also increases in ischemic conditions 
(Jalowy et al., 1999). Adrenal chromaffin cells which are functionally 
comparable to postganglionic adrenergic nerves have been found to express 
renin and prorenin (Wang et al., 2002). Also, neurons throughout the brain 
express renin (Lavoie et al., 2004). Several groups have observed a 
significant elevation of cardiac renin following myocardial ischemia (Passier et 
al., 1996; Clausmeyer et al., 2000).
Accordingly, the aim of this study was to explore the possibility that 
cSNE may possess renin and thereby have the capacity to form ANG II. If 
cSNE do express renin, this would suggest local, perhaps increased ANG II 
formation in myocardial ischemia. As shown in Figure 2.1, this ANG II could 
act at pre-synaptic ATi-receptors, further exacerbating carrier-mediated NE 
release and cardiac arrhythmias. Furthermore, released NE also enhances
2 3
Thesis Christina J. Mackins
NHE activity (Karmazyn et a!., 1999) and could result in a vicious cycle. Thus, 
prevention of local ANG II formation in cSNE may offer cardioprotection in 
ischemic conditions.
Angiotensinogen 
\  renin
ANG
ACEANG
N c  /  \
NET
NE
Na
Figure 2.1 Schematic illustrating the potential role of renin in ischemic 
cardiac sympathetic nerve endings. Abbreviations: ACE, angiotensin- 
converting enzyme; ATiR, angiotensin (type 1) receptor; NET, NE transporter; 
NHE, Na^/H^ exchanger.
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2.2 Methods
Global perfusion of rat hearts. This procedure w/as conducted by Dr. 
Ulrich Schaefer. Wistar rats weighing 250-300 g were killed by cervical 
dislocation under light anesthesia with CO2 vapor. After rapidly dissecting 
away the rib cage, hearts were isolated and hung on a Langendorff apparatus 
(Hatta et al., 1999). Control hearts were perfused for 70 min with Ringer’s 
solution of composition: 154 mM NaCI, 5.61 mM KCI, 2.16 mM CaCb, 5.95 
mM NaHCOs and 5.55 mM glucose. Ischemic hearts were perfused for 30 
min to stabilize prior to 40 min stop-flow global ischemia. Synaptosomes 
were then prepared from rat hearts as described below.
Preparation of rat cardiac and human atrial synaptosomes. This 
procedure was conducted by Dr. Nahid Seyedi. Whole hearts or atrial 
specimens were freed from fat and connective tissue and minced in ice-cold 
0.32 M sucrose. Synaptosomes were isolated as previously described 
(Seyedi et al., 2005). Briefly, minced tissue was digested with 120 mg 
collagenase per gram of wet heart for 1 hour at 37°C. After low-speed 
centrifugation (10 min at 120 g), the resulting pellet was suspended in 10 
volumes of 0.32 M sucrose and homogenized with a Teflon/glass 
homogenizer. The homogenate was spun at 650 g for 10 min, and the pellet 
was re-homogenized and re-spun. The pellet containing cellular debris was 
discarded, and the supernatants from the last two spins were combined and 
equally subdivided into four to eight tubes and re-centrifuged for 20 min at
20,000 g at 4°C. These pellets, which contained cardiac synaptosomes, were 
resuspended in HEPES-buffered saline (MBS containing 50 mM HEPES, pH
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7.4, 144 mM NaCI, 5 mM KCI, 1.2 mM CaCIa, 1.2 mM MgCb, and 10 mM 
glucose).
Chemical induction of ischemia in human atrial synaptosomes.
Synaptosomes were resuspended either in MBS (500 pi, normoxic conditions) 
or in glucose-free MBS, which contained the reducing agent sodium dithionite 
(500 pi, ischemic conditions), and incubated in the absence or presence of 
angiotensinogen (for 1 h) or other pharmacological agents for 20 min in a 
water bath at 37®C prior to ischemia. Ischemia was induced by incubating 
atrial synaptosomes for 70 min in HBS bubbled with 95% N2 and 5% CO2 , 
containing sodium dithionite (3 mM; PO2 -0  mm Hg, pH -7.3; ischemic NE 
release) (Hatta et al., 1997). Matched control synaptosomes were incubated 
for an equivalent length of time with oxygenated HBS (normoxic NE release). 
Drugs, when used, were continued throughout the entire normoxic and 
ischemic periods.
Preparation of guinea pig cardiac synaptosomes. This procedure 
was conducted by Dr. Nahid Seyedi. Guinea pigs were anesthetized with CO2 
and exsanguinated. The ribcage was rapidly opened and the heart dissected 
away. A cannula was inserted in the aorta and the heart was perfused at 
constant pressure (40 cm H2 O) in a Langendorff apparatus with oxygenated 
Ringer's solution (Seyedi et al., 2005). In the experiments depicted in Figure 
2.10, hearts were challenged with an intra-aortic bolus injection of compound 
48/80 (300 pg) while being perfused with normal Ringer’s or with Ringer’s 
containing lodoxamide (10 pM). Hearts were subsequently freed from fat and 
connective tissue and minced in ice-cold 0.32 M sucrose containing 1 mM
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EGTA, pH 7.4. Synaptosomes were isolated as described above and 
incubated with the renin substrate human angiotensinogen (2.4-240 nM) in a 
water bath at 37°C either in the absence or presence of the renin inhibitor 
BILA2157 (10 nM), the ACE inhibitor enalaprilat (30 nM), or the ATi-receptor 
blocker EXP3174 (10 nM). Controls were incubated for an equivalent length 
of time without angiotensinogen.
Norepinephrine Assay. Following incubation, synaptosomal samples 
were centrifuged at 20,000 g for 20 min, 4°C. The supernatant was assayed 
for NE content by high-pressure liquid chromatography with electrochemical 
detection (Hatta et al., 1997). Perchloric acid and EDTA were added to 
samples to achieve final concentrations of 0.01 N and 0.025%, respectively. 
The NE present in the effluent was adsorbed on acid-washed alumina 
adjusted at pH 8.6 with Tris-2% EDTA buffer, and then extracted into 150 pi 
perchloric acid (0.1 N). These final sample aliquots were injected onto a 3-pm 
CDS reverse-phase column (3.2 x 100 mm; Bioanalytical Systems Inc., West 
Lafayette, IN) with an applied potential of 0.65 V. The mobile phase consisted 
of monochloroacetic acid (75 mM), sodium EDTA (0.5 mM), sodium 
octylsulfate (0.5 m'M), and acetonitrile (1.5%) at pH 3.0. The flow rate was
1.0 ml/min. Dihydroxybenzylamine was added to each sample as an internal 
standard prior to alumina extraction and used for calculation of the recovery 
during the extraction procedure. The detection limit was approximately 
0.2pmol. Synaptosomal pellets were assayed for protein content, by a 
modified Lowry procedure (Markwell et al., 1978).
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Western Blotting. Tissue homogenates, cell lysates or pure protein 
were prepared with 2X No vex Tris-glycine SDS sample buffer (Invitrogen 
Corp., CA) and boiled for 5 min before separation by electrophoresis on Tris- 
glycine SDS-polyacrylamide gels (Invitrogen Corp. CA). Electrophoresis was 
carried out at 200 V, 40 mA per gel for 1 h. Gels were soaked in transfer 
buffer (25 mM Tris-base/0.2 M glycine/10% methanol, pH 8.5) and 
electrotransferred to poly(vinylidene difluoride) (PVDF) membranes 
(Immobilon-P, Millipore, MA) for 90 min at 25 V, 100 mA at room temperature. 
Membranes were blocked for at least 2 h in blocking buffer [Tris-buffered 
saline (TBS) containing 0.1% Tween 20 and 5% (wt/vol) nonfat dry milk]. 
Primary antibodies were incubated with the PVDF overnight at 4°C, diluted 
appropriately in primary Ab dilution buffer (TBS containing 0.1% Tween 20, 
5% BSA). The PVDF was washed three times with TBS, and then horseradish 
peroxidase-coupled secondary Ab was added at a 1:2000 dilution in blocking 
buffer for 1 h. After three further TBS washes, the protein of interest was 
detected by using enhanced chemiluminescence (LumiGLO; Cell Signaling 
Technology Inc., MA) and by exposure to x-ray film (BiomaxMR, Kodak, NY).
Antibodies: The polyclonal renin antibody, BRI (Campbell et al.,
1996), raised in rabbit to human recombinant renin was kindly donated by Dr 
D. F. Catanzaro (Weill Medical College). Human kidney renin used for BRI 
pre-adsorption was purchased from Calbiochem, CA. Mouse monoclonal 
antibody against rat renin (Barlucchi et al., 2001) was purchased from Swant 
(Switzerland). Anti-sarcomeric myosin heavy chain antibody, MF20 (Bader et 
al., 1982) was kindly donated by Dr D. A. Fischman (Dept, of Cell and
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Developmental Biology, Weill Medical College). The mouse monoclonal 
cathepsin D antibody was purchased from Calbiochem, CA.
Preparation of frozen tissue sections. Rat hearts were excised and 
globally perfused with Ringer’s solution, as described above, fixed in 4%  
paraformaldehyde and then placed in 30% sucrose for 2 h at 4°C to 
cryoprotect the tissue. Rat hearts or human right atrial specimens were 
embedded in frozen tissue medium by snap-freezing in liquid N2 . Sections of 
10 pm were prepared on glass slides and stored at 80° C until use.
Immuno- and histochemistry. 10 pm tissue sections permeabilized 
for 10 min at 37°C with a solution containing 4% FBS and 0.3% Triton X-100 
dissolved in PBS were washed in PBS, then blocked in 10% FBS for 1 h at 
37°C before incubation with primary antibody. Following primary antibody 
incubation, sections were washed again before incubation for 1 h at 37°C with 
the appropriate fluorochrome-conjugated secondary antibody. Sections were 
fixed in 4% paraformaldehyde for a few minutes at room temperature, 
mounted and then visualized under a fluorescence microscope. In 
experiments where tissue was stained with toluidine blue (Sigma, MO) (0.25%  
in acetic acid, pH 2.0), the procedure of Kiernan ef al. was followed. In 
instances where tissues were co-stained, staining with toluidine blue was 
performed after the tissue had been immunostained.
Antibodies: All secondary antibodies were purchased from Molecular 
Probes Inc., OR: polyclonal renin antibody, BRI with TRITC-conjugated anti­
rabbit IgG or FITC-conjugated anti-rabbit; monoclonal mouse renin antibody 
(Swant, Switzerland) with FITC-conjugated anti-mouse IgG; polyclonal rabbit
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histamine antibody (Accurate Chemical and Scientific Corp., NY) with FITC- 
conjugated anti-rabbit IgG; polyclonal goat synapsin la/b antibody (Santa 
Cruz, CA) with FITC-conjugated anti-goat IgG; monoclonal mouse cathepsin 
D antibody with FITC-conjugated anti-mouse IgG.
RT-PCR. Total RNA was extracted from human kidney tissue, human 
right atrial tissue and the HMC-1 cell line using RNA STAT-60 reagent (Tel- 
Test “B” Inc., TX). One microgram of total RNA from each sample was 
reverse transcribed and assayed by FOR using QIAGEN’s OneStep RT-PCR 
Kit (Valencia, CA). Sense and antisense primers were:
Human renin: 5-TCTCAGCCAGGACATCATCA-3’ and
5-AGTGGAAATTCCCTTCGTAA-3’ (Becker et al., 2000); 
(3-actin: 5’-GCTCGTCGTCGACAACGGCTC-3’ and
5-GCTCTTCTACTGGGTCTAGTACAAAC-3’.
The amplification profile utilized was as follows: 50°C 30 min, 95°C 15 min, 
then 94°C 30 sec, 55°C 30 sec, 72°C 1 min (40 cycles) and finally 72°C 10 
min. PCR products generated were 288 and -350  bp, for renin and p-actin 
respectively. PCR products were analyzed by agarose gel electrophoresis 
and ethidium bromide staining. The renin RT-PCR product from HMC-1 RNA 
was extracted from the agarose gel by using GENECLEAN II (QBIOgene, 
Carlsbad, CA); after ethanol precipitation to further purify and concentrate the 
DNA, samples were sent to the DNA Sequencing Resource Center (The 
Rockefeller University, New York) and run on a SpectruMedix 9610 DNA 
sequencer.
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Cell Culture. The human mast cell line, HMC-1, was provided to us by 
Dr I. Biaggioni (Vanderbilt University, TN). HMC-1 cells were maintained in 
suspension culture at a density between 3 and 9 x 10® cells/ml by dilution with 
Iscove’s modified Dulbecco’s medium supplemented with 10% fetal bovine 
serum, 2 mM glutamine, 50 U/ml penicillin, 50 U/ml streptomycin and 1.2 mM 
a-thioglycerol. Cells were kept at 37°C, 5% CO2 .
Immunocytochemistry. HMC-1 cells were grown on standard 22-mm 
glass coverslips for 48 h and rinsed free of media with PBS. Cells were fixed 
and permeabilized in PBS containing 3.7% PF and 0.3% Triton X-100, washed 
with PBS for 3 min and then blocked for 30 min at 37°C with 1 % BSA. After 
this, the cells were incubated with polyclonal rabbit BRI renin Ab (1:400) for 1 
h at room temperature. The cells were washed and then exposed to FITC- 
conjugated donkey anti-rabbit IgG (1:400) for 1 h at room temperature. After 
washing with PBS as above, coverslips were mounted and then visualized 
under a fluorescence microscope.
Renin Activity. Pooled confluent flasks or individual wells of HMC-1 
cells were pelleted and resuspended in HEPES buffer (pH 5.7, 1 mM EDTA) 
containing the mast-cell-degranulating agent compound 48/80 (100 or 20 
pg/ml; Sigma, MO). After 30 min, cells were spun down, and the renin- 
containing supernatant incubated with increasing concentrations of human 
angiotensinogen (Sigma, MO). Renin activity (ANG I formed) was then 
determined by using a GammaCoat Plasma Renin Activity ^^ ®l RIA kit 
(DiaSorin, Stillwater, MN). The selective renin inhibitor BILA2157 was 
generously provided to us by Boehringer Ingelheim.
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2.3 Results
Presence of renin in cardiac sympathetic nerve endings
Rat cSNE (cardiac synaptosomes) were probed with two renin-specific 
antibodies: BR1, a polyclonal antibody raised in rabbit to human recombinant 
renin (kindly donated by Dr D. F. Catanzaro, Weill Medical College) (Campbell 
et al., 1996) and a mouse monoclonal antibody to rat renin purchased from 
Swant, Switzerland (Barlucchi et al., 2001) (Figure 2.2A). Both antibodies 
showed clear immunoreactivity in lanes loaded with rat kidney homogenate in 
the expected range for renin, -4 0  kDa. Discrete bands of similar size were 
also present in control rat cSNE. In rat, at least three isoforms of renin are 
known to exist (Matoba et al., 1978). Furthermore, relative to control rat 
cardiac synaptosomes there was an increase in the abundance of renin in 
synaptosomes prepared from hearts subjected to ischemia-reperfusion for 40 
minutes (Figure 2.2B).
Carrier-mediated NE release from cardiac sympathetic nerve endings
Using a model of cardiac neuronal ischemia developed in our 
laboratory, the significance of a cardiac renin-angiotensin system in 
modulating carrier-mediated NE release was investigated. Synaptosomes 
isolated from surgical specimens of human right atrium were incubated for 70 
min either in control (95% O2 , 5% CO2) or anoxic/ischemic (glucose-free, 3 
mM sodium dithionate, 95% N2 , 5% CO2 ) conditions. Characteristically, 
ischemic conditions triggered a significant carrier-mediated release of 
endogenous NE from the synaptosomes; i.e., the release could be markedly 
diminished by both the NE transporter inhibitor desipramine (DMI; 300 nM) 
and the NHE inhibitor El PA (30 pM). Notably, this carrier-mediated NE
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release was facilitated by the renin substrate angiotensinogen (400 nM), 
whilst having no effect upon basal NE release. Furthermore, the 
angiotensinogen-enhanced carrier-mediated NE release could be diminished 
by inhibitors of renin (BILA2157BS; 100 nM) and ACE (enalaprilat; 3 pM), and 
also by ATi-receptor blockade (EXP3174; 300 nM) (Figure 2.3). These 
pharmacological data are suggestive of a cardiac renin-angiotensin system 
located within sympathetic nerve endings which becomes activated only 
under ischemic conditions.
Cardiac Synaptosomal Purity
Since the issue of where in the heart renin exists is so controversial 
(Dostal and Baker, 1999), it was necessary to test the purity of the cardiac 
synaptosomal preparation. This was verified by Western blot using MF20, an 
antibody specific for sarcomeric myosin heavy chains (Bader et al., 1982). 
Present in cardiac tissue but not in nerve endings, sarcomeric myosin was an 
ideal marker of synaptosomal purity. Equal amounts of protein for human 
atrial homogenate and synaptosomes were run in parallel on the same gel 
(Figure 2.4). Although significantly fainter than in the atrial homogenate, a 
205 kDa band corresponding to human myosin was detectable in the 
synaptosomal preparation. Therefore, the possibility had to be considered 
that renin presence in the synaptosomal preparation may in fact be a 
consequence of contamination that occurred during isolation.
immunohistochemica! Detection of Renin in Heart Sections
Having demonstrated that NE release from cSNE can be modulated by 
interfering pharmacologically with components of the renin-angiotensin
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system, but suspecting that the renin present in cardiac synaptosomes may 
be a contamination product, immunohistochemistry was used as a means of 
visualizing renin localization in the heart. Cryostat sections of 
paraformaldehyde-fixed rat hearts were initially screened for renin by indirect 
immunofluorescence microscopy. Both renin antibodies, the rabbit polyclonal 
BR1 (1:500) and mouse monoclonal (1:100) were used, followed by TRITC- 
conjugated anti-rabbit IgG (1:500) and FITC-conjugated anti-mouse IgG 
(1:500), respectively. Surprisingly, no structures resembling myocytes or 
nerves immunoreacted with either of the renin antibodies. Instead, striking 
immunoreactivity was observed in distinct cells that were -10  pm in diameter. 
Figures 2.5A and B show two cells in the same field of view stained by both 
renin antibodies. Figures 2.5C and D were generated by primary incubation 
of rat ventricle sections with the polyclonal BRI renin antibody (1:500), 
followed by FITC-conjugated anti-rabbit IgG (1:500), and were taken at higher 
magnification. It is clear that the contents of these immunoreactive cells are 
granular. Furthermore, the observed immunoreactivity was abolished in 
negative control conditions where sections were incubated with the secondary 
antibody alone, or if the polyclonal BRI antibody was pre-adsorbed with 
excess human kidney renin, as in Figure 2.5E. Based upon morphology, size 
and abundance, it was speculated that these renin-positive cells may be 
cardiac mast cells.
To confirm the presence of renin-positive cells, possibly mast cells, in 
the heart, immunohistochemistry was repeated in sections taken from surgical 
specimens of human right atrium. Indeed, after incubation with the polyclonal 
BRI renin antibody (1:500), followed by FITC-conjugated anti-rabbit IgG
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(1:500), immunoreactive cells similar to those seen in rat ventricle sections 
were observed. A representative renin-immunoreactive cell is shown in 
Figure 2.6A. Total RNA was extracted from the remaining human heart 
tissue. After reverse transcription, this RNA was assayed by PCR using 
sense and anti-sense primers specific for human renin (Becker et al., 2000). 
Figure 2.6B shows PCR products for human kidney and human cardiac tissue 
run on an ethidium bromide-stained agarose gel. p-actin was assayed as 
control. As previously reported (Endo-Mochizuki et al., 1995), human cardiac 
tissue was found to express mRNA for renin, further complementing the 
Western, NE release and immunohistochemical data.
Co-localization of renin to cardiac mast cells
Further characterization was required to prove that the renin- 
immunoreactive cells observed in rat and human heart tissue were in fact 
cardiac mast cells. A classical histochemical stain for mast cells is toluidine 
blue (Kiernan, 1981), which stains the acidic intracellular compartments of 
granulated cells. Cryostat sections of paraformaldehyde-fixed rat heart (10 
pm) were stained with 0.25% toluidine blue in acetic acid. Every section of rat 
ventricle studied contained some toluidine blue-positive cells. Figure 2.7A (i) 
shows a cluster of cells that exhibit toluidine blue staining under transmitted 
light. More important was to demonstrate that these toluidine blue-positive 
cells were the same cells that were renin-positive. Hence, sections of rat 
ventricle incubated with the polyclonal BRI renin antibody (1:500) followed by 
FITC-conjugated anti-rabbit IgG (1:500) were also stained with toluidine blue 
(0.25% in acetic acid). Figures 2.7A (ii and iii) are the same field of view 
under transmitted light and epifluorescence, respectively. The two cells
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indicated by arrows are seen to contain toluidine blue-stained granules, under 
transmitted light (ii). The same two cells are illuminated under 
epifluorescence, indicating them to be renin-positive also (iii). Notably, 
myocytes visible to the left of the two toluidine blue-stained cells under 
transmitted light (ii) did not show any visible immunoreactivity with BR1, the 
polyclonal renin antibody (iii).
Since toluidine blue does not selectively stain mast cells, it was 
important to confirm mast cell identity by another means. Mast cells are 
characteristically rich in histamine (Marone et al., 1995a; Marone et al., 1997), 
therefore sections of rat heart were incubated with a polyclonal rabbit 
histamine antibody (1:500; Accurate Chemical and Scientific Corp., NY) and 
the monoclonal renin antibody (1:100) followed by FITC-conjugated anti-rabbit 
IgG (1:500) and TRITC-conjugated anti-mouse IgG (1:500), respectively. As 
shown in Figure 2.7B, histamine (green) was found to co-localize to the renin- 
positive cells (red). Collectively, these data indicate that the renin-positive 
cells found in the heart are most likely mast cells.
Polyclonal BRI renin antibody specificity
Given that mast cells are known to contain an array of proteases, the 
specificity of the polyclonal BRI renin antibody was investigated. Upon 
BLAST analysis of the protein sequence of human kidney renin, the only 
potential candidate for cross-reactivity of the BRI renin antibody was 
cathepsin D, which is -60%  homologous to renin (Figure 2.8A). Indeed, 
cathepsin D is capable of cleaving angiotensinogen to ANG I, via a renin- 
independent pathway (Resende and Mill, 2002), and this protease is also
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present in mast cells (Baram et al., 1999). Gels were loaded with rat kidney 
homogenate and pure cathepsin D (from human liver) in alternating lanes. 
After Western blotting, membranes were probed with either the polyclonal 
BRI renin antibody (1:12,500) or a monoclonal cathepsin D antibody (1:100) 
(Figure 2.8B). The polyclonal BRI renin antibody showed a clear band 
corresponding to renin in lanes loaded with rat kidney homogenate, -4 0  kDa; 
in contrast there was no immunoreactivity in lanes loaded with pure cathepsin 
D. The monoclonal cathepsin D antibody shows immunoreactivity -3 4  and 48 
kDa in lanes loaded with pure cathepsin D, corresponding to its enzymatically 
active form and a subunit of the heterodimer, respectively (Morisset et al., 
1986). Consistent with its presence in the kidney (Goto et al., 2001), a faint 
band -4 8  kDa was also observed in lanes loaded with rat kidney homogenate. 
These results strengthen the data thus far, by confirming that the polyclonal 
BRI renin antibody does not cross-react with cathepsin D. Since the 
monoclonal cathepsin D antibody also did not cross-react with renin, it was 
possible to use the two antibodies together to co-localize renin and cathepsin 
D. Sections of rat ventricle were incubated with the polyclonal BRI renin 
antibody (1:500) and the monoclonal cathepsin D antibody (1:500), followed 
by TRITC-conjugated anti-rabbit IgG (red; 1:300) and FITC-conjugated anti­
mouse IgG (green; 1:300), respectively. As expected, cardiac mast cells 
stained for both renin and cathepsin D, but seemingly in distinct 
compartments (Figure 2.8C).
Mast cell proximity to cardiac nerves
In light of the finding that renin appears to be localized in cardiac mast 
cells rather than within cardiac sympathetic nerves, it was important to
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determine if renin released from mast cells could ultimately influence NE 
release. Synapsin, a protein expressed exclusively by neurons (Sudhof et al., 
1989) was used as a marker to identify cardiac nerves. As previously, 
sections of rat heart were incubated with the polyclonal BR1 renin antibody 
(1:500) in addition to a synapsin la/b antibody (Santa Cruz, CA; 1:100), 
followed by TRITC-conjugated anti-rabbit IgG (1:500) and FITC-conjugated 
anti-goat IgG (1:300), respectively. The slides were visualized in 0.5 pm 
sections on a Leica confocal microscope. There did not appear to be any co­
localization of the renin antibody to the synapsin-stained cardiac nerves. 
However, as shown in Figure 2.9, renin-containing mast cells (red) are in very 
close proximity to the nerves (green). Thus, mast cell degranulation could 
conceivably release renin and thereby generate local AN G II levels capable of 
augmenting carrier-mediated NE release from cardiac sympathetic nerves.
Mast cell derived renin and NE release from cardiac synaptosomes
In as much as mast cell degranulation may result in increased renin 
incorporation into the cardiac synaptosomal preparation, the possibility that 
renin derived from cardiac mast cells may activate the renin-angiotensin 
system in the proximity of cardiac sympathetic nerve endings, ultimately 
enhancing NE release, was investigated. The classical mast cell- 
degranulating agent compound 48/80 (Levi and Allan, 1980) and the mast cell 
stabilizer lodoxamide (Johnson and Sheridan, 1986) were used. 
Synaptosomes were isolated from untreated (control), 48/80 challenged and 
48/80 challenged lodoxamide-treated hearts, and were incubated with 
increasing concentrations of the renin substrate angiotensinogen. As shown 
in Figure 2.10A, NE release from cSNE increases with angiotensinogen
3 8
Thesis________________________________________________________  Christina J. Mackins
concentration. NE release was enhanced in cSNE isolated frorn 48/80- 
treated hearts, whereas it was markedly inhibited in cSNE from hearts 
perfused with lodoxamide prior to 48/80 treatment. Furthermore, the 48/80- 
induced enhancement of NE release from cSNE was prevented by the 
selective renin inhibitor BILA2157BS (10 nM; Figure 2.1 OB), the ACE inhibitor 
enalaprilat (30 nM), or by the ATi-receptor antagonist EXP3174 (10 nM; 
Figure 2.100).
Detection of renin in a cultured mast cell line
Due to novelty of the finding that cardiac mast cells contain renin, 
further verification was sought in a human cultured mast cell line. The HMC-1 
cell line expresses a typical mast cell phenotype with the exception that it is 
chymase deficient (Nilsson et al., 1994). Investigation of HMC-1 cells by 
means of RT-PCR confirmed that this cultured mast cell line expresses renin 
at the mRNA level (Figure 2.11). Furthermore, sequencing of the HMC-1 
renin RT-PCR product revealed 100% homology to human renin mRNA 
(GenBank accession no. NM_000537.2) by BLAST analysis. HMC-1 also 
express renin protein, as confirmed by Western blot and 
immunocytochemistry (Figure 2.11). Nevertheless, the significance of this 
finding depends upon mast cell-derived renin protein having the capacity to 
convert angiotensinogen to ANG I upon degranulation, so it was crucial to 
demonstrate that mast cell renin is active. To address this, HMC-1 cells were 
grown to confluence and treated with a classical mast-cell-degranulating 
agent, 48/80 (100 pg/ml) (Levi and Allan, 1980). The mast cell releasate was 
incubated with increasing concentrations of angiotensinogen and then 
assayed for renin activity (ANG I formation) by radioimmunoassay. Figure
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2.12A shows the ooncentration-response curve for ANG I formation in HMC-1 
cell releasate generated as a function of angiotensinogen concentration. The 
amount of ANG I formed increased with angiotensinogen concentration. ANG 
I was generated in the absence or presence of the specific renin inhibitor, 
BILA2157 (100 nM; IC50 = 1 nM) (Simoneau et al., 1999). Approximately 70% 
of the total ANG I formed was BlLA-sensitive, demonstrating that mast cell- 
derived renin is indeed active.
Having established that HMC-1 cells release active renin upon 
degranulation, it was considered whether mast cells are capable of re- 
synthesizing renin. The same population of HMC-1 cells were exposed twice 
to 48/80 (20 pg/ml), 48 hours apart. The releasates from both degranulations 
were incubated with angiotensinogen (240 nM) and subsequently assayed for 
renin-specific ANG I formation. As shown in Figure 2.12B, in releasates from 
the same population of HMC-1 cells, both initially and 48 hours later, BI LA- 
sensitive renin accounted for -70%  of the total ANG I forming activity 
measured. This suggests that HMC-1 do have the capacity to re-synthesize 
renin.
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Figure 2.2 A. Presence of renin in rat cardiac synaptosomes. Renin 
Western blots utilizing two renin-specific antibodies: i) BR1 polyclonal 
(1:12,500), and ii) Swant monoclonal (1:400). Rat kidney homogenate (K; 50 
pg) was run as control alongside control rat cardiac synaptosomes (cSNE; 
130 pg). Arrows indicate renin band. B. Relative renin abundance 
increases in ischemic cSNE. Representative lanes from a renin Western 
blot using BRI. Equal amounts (125 pg) of cSNE from control and globally 
ischemic hearts were run in duplicate on the same gel. Kidney homogenate 
(20 pg) was run as a control. Arrow indicates renin band.
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Figure 2.3 inhibitors of renin and ACE, and ATi-receptor biockers 
decrease carrier-mediated NE release facilitated by angiotensinogen in a 
human model of cardiac neuronal ischemia. NE release from 
synaptosomes isolated from surgical specimens of human right atrium. 
Synaptosomes were incubated for 70 min either in control (normal MBS, 
gassed with 95% O2 and 5% CO2 ) or anoxic/ischemic conditions (glucose-free 
MBS, containing 3 mM sodium dithionite and gassed with 95% N2 and 5% 
CO2 ), in the absence or presence of angiotensinogen (400 nM) alone or with 
the renin inhibitor BILA2157BS (BILA.100 nM), the ACE inhibitor enalaprilat 
(ENAL, 3 pM) or the ATi-receptor antagonist EXP3174 (EXP, 300 nM). Bars 
(mean ± SEM.; n = 8-28) represent total NE released during each 70-min 
incubation period. *p< 0.05 vs. control ischemic NE release in the absence of 
angiotensinogen, and fp<  0.05 vs. ischemic NE release in the presence of 
angiotensinogen, by one-way AN OVA followed by Dunnett multiple 
comparison test.
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Figure 2.4 Contamination of cardiac synaptosomes with myosin.
Western blot probed with an antibody specific for sarcomeric myosin, MF20. 
Lanes were loaded equally with atrial homogenate (A; 1.5 pg) and rat cardiac 
synaptosomes (Syn; 1.5 pg). Chicken pectoralis myosin (CP) was run as a 
positive control. Arrows indicate myosin band.
Figure 2.5 Immunohistochemical detection of renin in rat ventricle 
sections. Staining of the same population of rat cardiac renin-positive cells 
observed using polyclonal BR1 (A) and Swant monoclonal (B) antibodies, 
bars = 5 pm. Images of rat cardiac renin-positive cells stained with BR1 at 
higher magnification 40x (C) and 100x (D), bars = 10 pm and 4 pm, 
respectively. Staining was not observed when BRI was pre-adsorbed with 
excess human kidney renin (E), bar = 1 0  pm.
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Figure 2.6 A. Immuno-histochemicai detection of renin in human heart.
Polyclonal renin antibody, BR1, staining a cardiac renin-positive cell in a 
section of right atrial tissue, bar = 10 pm. B. Detection of renin mRNA in 
human heart tissue. RT-PCR of human kidney and human right atrial tissue 
using renin-specific primers (A) and p-actin primers (B) as control, m = marker 
lane.
A.
1
B.
Figure 2.7 A. Co-locaiization of renin to rat cardiac mast ceils. Toluidine 
blue staining of cardiac mast cells in a section of rat ventricle, bar = 20 pm (i). 
Panel ii shows toluidine blue stained mast cells at a higher magnification, bar 
= 5 pm. Mast cells in the same section also stained with the polyclonal renin 
antibody, BRI (iii). B. Co-localization of renin (red) and histamine (green) 
within a cardiac mast cell using BRI and a histamine-specific antibody, bar = 
10 pm.
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Figure 2.8 Considering cathepsin D as a potential candidate for cross­
reactivity of the renin BR1 antibody. A. Protein-protein BLAST analysis of 
human renin (Query) vs. human cathepsin D (Sbjct). B. Western blot of rat 
kidney homogenate (Kid; 25 and 50 pg/lane) and pure cathepsin D (CD; 100 
and 500 ng/lane) probed with the polyclonal BRI renin antibody (left) and a 
cathepsin D antibody (right). Arrows indicate renin and cathepsin D bands. 
C. Rat cardiac mast cell co-stained with renin BRI (red) and cathepsin D 
(green) antibodies. Bar = 5 pm.
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Figure 2.9 Mast cells (MC; red) and nerves (N; green) viewed by 
confocal microscopy. A 0.5 pm slice of rat heart was co-stained with anti­
renin BR1 and anti-synapsin antibodies. Bar = 40 pm.
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Figure 2.10 Release of NE from guinea-pig heart synaptosomes 
incubated with human angiotensinogen (2.4-240 nM). A; prior to 
synaptosome isolation, hearts were untreated (control) or challenged with 
compound 48/80 (300 pg, bolus injection), preceded or not by lodoxamide (10 
pM). Note overlapping data points with 3 nM angiotensinogen. 
Synaptosomes were incubated with: B, BILA2157 (10 nM); C, enalaprilat (30 
nM) or EXP3174 (10 nM). Points are means (n=4; ±SEM; basal NE release 
was 1.45 ± 0.03 pmol/mg protein). For reference, the control curve shown in 
panel A is repeated in B, and the 48/80 curve shown in panel A is repeated in 
B and C.
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Figure 2.11 Detection of renin in a cultured mast cell line, HMC-1. A.
Western blot probed with BRI (1:12,500) showing HMC-1 cells (50 pg/lane) 
run alongside rat kidney (K; 20 pg/lane) as a control. B. Immunostaining of 
renin in HMC-1 cells using BRI, bar = 1 0  pm. C. RT-PCR of human kidney 
and HMC-1 cells using renin-specific primers (A) and p-actin primers (B) as 
control. M = marker lane. BLAST analysis of the HMC-1 renin RT-PCR  
product (Query) vs. human kidney renin (Sbjct) indicates 100% homology.
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Figure 2.12 Renin activity measurements in HMC-1 releasate. A. ANG I
formed (pg/ml/hr) in HMC-1 releasate incubated with increasing 
concentrations of human angiotensinogen (0-400 nM), in the absence (blue) 
and presence (red) of BILA (100 nM) (mean ± SEM; n = 3). B. ANG I formed 
(pg/ml/hr/10^ cells) in HMC-1 releasate from two consecutive 48/80 (20 pg/ml) 
treatments of the same group of cells (initial (time zero) and 48 hrs later). 
Releasate was incubated with angiotensinogen (240 nM), in the absence 
(blue) and presence (red) of BILA (100 nM) (mean ± SEM; n = 12).
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2.4 Discussion
Originally, the aim of this study was to investigate the possibility that 
cSNE express renin, which becomes elevated under ischemic conditions. 
The subsequent increase in locally generated ANG II could then act upon 
ATi-receptors located on cSNE in an autocrine manner, thereby exaggerating 
the ischemia-induced carrier-mediated NE release (as outlined in Figure 2.1). 
Certainly, initial findings were supportive of this hypothesis. Western blots of 
rat cSNE using both polyclonal and monoclonal renin-specific antibodies 
revealed the presence of a band in the expected -4 0  kDa range for renin. 
Furthermore, the renin band seen in cSNE prepared from hearts subjected to 
40 minutes ischemia-reperfusion was more intense relative to the 
corresponding band seen in control cSNE (Figures 2.2A and B). In a model of 
cardiac neuronal ischemia, modulation of carrier-mediated NE release by 
pharmacological intervention at different levels was also indicative of a cSNE- 
linked renin-angiotensin system, which becomes activated only under 
ischemic conditions (Figure 2.3). However, in light of the fact that myosin was 
detectable in the cardiac synaptosomal preparation (i.e., contamination; 
Figure 2.4), the significance of data generated using cardiac synaptosomes 
had to be re-assessed. Hence, visualization of renin co-localized to intact 
cSNE by immunohistochemistry in paraformaldehyde-fixed rat heart sections 
was attempted. In disagreement with the original working hypothesis, no 
nerve-like structures immunoreacted with the monoclonal or polyclonal renin 
antibodies. Instead, granular, cell-like structures staining intensely for renin 
were seen (Figure 2.5). The same was observed in human right atrial tissue 
sections (Figure 2.6A), and consistent with others (Endo-Mochizuki et al..
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1995) renin mRNA was also detected by RT-PCR in human heart tissue 
(Figure 2.6B). Based upon size and general morphology, the possibility that 
the renin-positive cells were cardiac mast cells was considered. By staining 
sections of paraformaldehyde-fixed rat heart with a classical histochemical 
stain for mast cells (0.25% toluidine blue in acetic acid) (Kiernan, 1981), a 
clear co-localization with the renin-positive cells was demonstrated (Figure 
2.7A). Furthermore, there was co-localization of the renin-positive cells with 
an antibody to histamine, a classical mast cell mediator (Marone et al., 1995; 
Marone et al., 1997) (Figure 2 .7B ).
With novel evidence suggesting that cardiac renin is likely to be located 
in mast cells, the specificity of the renin antibodies was questioned. 
Encouragingly, both the monoclonal and polyclonal antibodies stained the 
same mast cell-like structures in sections of rat heart (Figures 2.5A and B). 
Since the polyclonal BR1 renin antibody was preferential for 
immunohistochemistry, its specificity was further tested in sections of 
paraformaldehyde-fixed rat kidney. As shown previously (Campbell et al.,
1996), only the site of renin synthesis (the vascular pole of the glomerulus) 
exhibited immunoreactivity with BRI. Importantly, immunoreactivity was not 
observed in kidney or heart negative controls, when the primary antibody 
incubation step was excluded. BRI immunoreactivity could also be abolished 
by pre-adsorption with an excess of human kidney renin (Figure 2.5E). To 
address the possibility of cross-reactivity, the renin amino acid sequence was 
subjected to BLAST analysis. The only likely candidate for cross-reactivity of 
BR1 was cathepsin D, a lysosomal-endosomal protease also found in mast 
cells, sharing -60%  homology with renin (Figure 2.8A). However, Western
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blots probing pure cathepsin D with the BR1 renin antibody revealed no 
immunoreactivity, indicating that cathepsin D was not the protease being 
detected in cardiac mast cells (Figure 2.8B). In addition, co-localization of 
renin and cathepsin D in sections of rat heart showed that these two 
proteases occupy distinct compartments within mast cells (Figure 2.8C).
Initially, it was believed that cSNE may express renin, which becomes 
elevated with ischemia. With cardiac renin seemingly being mast cell-derived, 
the significance of this preliminary hypothesis was re-assessed. If mast cells 
were located in the proximity of cSNE, the concept of locally formed ANG II 
acting on cSNE-located ATi-receptors, thereby exacerbating ischemia- 
induced carrier-mediated NE release, would still be possible. In sections of 
rat heart stained for renin in addition to the neuronal marker synapsin (Sudhof 
et al., 1989), renin was not co-localized with synapsin in nerve structures, 
however, the renin-containing mast cells were indeed found in close proximity 
to cardiac nerves (Figure 2.9). Despite the immunohistochemistry showing 
cardiac nerves to be void of renin, renin was still detected in synaptosomal 
preparations by Western blot (Figure 2.2). Could renin incorporation into 
cardiac synaptosomes be attributed to mast cell degranulation? Myocardial 
ischemia and associated oxygen free radical formation are known to trigger 
cardiac mast cell degranulation (Brooks et al., 1999; Frangogiannis et al., 
2002; Kruger et al., 1990). Hence, globally perfused control guinea pig hearts 
in the presence of the mast cell degranulator 48/80 (Levi and Allan, 1980; 
Janiszewski et al., 1990) were used to mimic the cardiac mast cell events that 
occur in ischemia. Renin has a high binding capacity for membranes by 
means of mannose-6-phosphate receptors and recently discovered renin
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receptors (Danser et al., 1997; Nguyen et al., 2003; Carey and Siragy, 2003), 
thus, renin incorporation into cSNE seems a likely occurrence. The possibility 
that mast cell-derived renin could influence NE release from cSNE incubated 
with increasing concentrations of angiotensinogen was tested. As predicted, 
angiotensinogen-dependent NE release was greater in cSNE isolated from 
48/80-treated hearts (i.e. with mast cells degranulated) compared to cSNE 
isolated from hearts treated with lodoxamide prior to 48/80 (i.e. with mast cells 
stabilized) (Figure 2.10A). Interestingly, NE release increased as a direct 
function of angiotensinogen concentration even without prior mast cell 
degranulation. This apparent incorporation of renin in control cSNE is likely 
attributable to mechanical mast cell degranulation in the process of 
synaptosomal isolation. The enhanced angiotensinogen-dependent NE 
release induced by degranulation of the cardiac mast cells with 48/80 prior to 
isolation of cSNE could be prevented by selective inhibition at different levels 
of the renin-angiotensin system: renin, ACE and ATi-receptors (Figure 2.10B 
and 0). Therefore, these findings demonstrate that mast cell degranulation 
releases sufficient renin to activate the cardiac renin-angiotensin system and 
ultimately promote NE release from cSNE via the formation of ANG II.
To further verify the novel finding that cardiac mast cells contain renin, 
the human cultured mast cell line, HMC-1 was tested. With the exception of 
being chymase-deficient, HMC-1 cells express a typical mast-cell phenotype 
(Nilsson et al., 1994), and are a widely used mast-cell model (Drexler and 
MacLeod, 2003; Welker et al., 1998; Werfel et al., 1996). Supportive of the 
findings in cardiac mast cells, HMC-1 cells also express renin mRNA as 
confirmed by RT-PCR (Figure 2.11C). In humans, several splice variants of
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the renin gene exist, giving rise to brain-, kidney- and lung-specific renin 
isoforms. Although the HMC-1 renin RT-PCR product generated using renin- 
specific primers targeted to exons 4 and 7 was 100% homologous to human 
renin, the possibility cannot be excluded that mast-cell renin may represent a 
novel renin isoform. The known human tissue-specific renin mRNA isoforms 
result from alternative transcriptional start sites within intron A (Sinn and 
Sigmund, 2000).
As demonstrated by Western blot and immunocytochemistry (Figure 
2.11A and B), HMC-1 cells also express renin protein. More importantly, it 
was shown that upon release from HMC-1, this renin protein is active and has 
the capacity to form ANG I from angiotensinogen (Figure 2.12A). This proves 
that renin released from mast cells is functional and has the capacity to initiate 
the activation of a local renin-angiotensin system.
Mast cells are unique in their capability of undergoing several cycles of 
degranulation and regranulation. Others have shown that mast cells can 
release granule-associated proteins such as (3-hexosaminidase and 
upregulate cytokine expression having recovered from a prior degranulation 
(Xiang et al., 2001). Likewise, this work demonstrates that HMC-1 cells are 
capable of releasing active renin 48 hours following an initial degranulation 
(Figure 2.12B). This suggests that mast cells are capable of synthesizing 
renin. Although the view has been expressed that the majority of cardiac 
renin derives from the circulation (Danser et al., 1994), mast cells are not 
known to express mannose-6-phosphate receptors (van Kesteren et al., 1997)
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or recently discovered renin receptors (Nguyen et al., 2002), mechanisms by 
which renin is thought to internalize into cardiac cells.
The discovery of renin in cardiac mast cells is of major significance for 
our understanding of the local cardiac renin-angiotensin system, including its 
major contributing role to the release of NE associated with myocardial 
ischemia. Moreover, the possibility that renin could exist in mast cells of other 
major organs in the body has vast clinical implications.
The overall basis of the original hypothesis remains unchanged: the 
concept of a cardiac renin-angiotensin system, which becomes activated in 
myocardial ischemia, and that generates ANG II in close proximity of cSNE. 
Whereas it was previously thought that ANG II acts in an autocrine manner, 
being released from cSNE and activating ATi-receptors also located on 
cSNE, the current belief is that ANG II is formed in the interstitium and acts on 
cSNE-located ATi-receptors in a paracrine fashion. Figure 2.13 shows the 
sequence of events believed to occur in protracted myocardial ischemia. 
Myocardial ischemia triggers degranulation of cardiac mast cells, 
demonstrated to be a novel source of renin. The released renin has a high 
affinity for cell membranes including those of cSNE that are closely apposed 
to mast cells. Angiotensinogen, the substrate for renin, and ACE, the enzyme 
responsible for converting ANG I to ANG II, are known to exist in the 
interstitial fluid of the heart (Dell'italia et al., 1997; de Lannoy et al., 2001). 
Hence, free/bound mast cell-derived renin could cleave angiotensinogen 
forming ANG I, followed by subsequent conversion to ANG II. This locally 
formed ANG II could interact with ATi-receptors on cSNE thereby stimulating
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NHE activity. The resultant rise in Na^ within nerve endings would cause a 
reversal of the NE transporter, thus exacerbating the excessive carrier- 
mediated NE release associated with myocardial ischemia.
In summary, it is proposed that mast cells are a novel source of renin in 
the heart. Ischemia-induced mast cell degranulation could be a pivotal step in 
activating the cardiac renin-angiotensin system, and may play a significant 
role in the excessive carrier-mediated NE release associated with cardiac 
arrhythmias and consequent dysfunction, including sudden cardiac death. 
Notably, sudden cardiac death accounts for more than half of all 
cardiovascular deaths, and a large proportion of these deaths are attributed to 
ischemia-induced ventricular fibrillation (Cascio et al., 2005).
Angiotensinogen
ANG W
MAST CELL
renin
MYOCARDIAL ISCHEMIA
ACE
©
Interstitium
( \ 
Sympathetic nerve ending
+  ^Free tN a
Figure 2.13 A schematic representation of the modified hypothesis.
Myocardial ischemia induced degranulation of renin-containing mast cells 
activates a local renin-angiotensin system cascade, thereby exacerbating 
carrier-mediated NE release from cardiac sympathetic nerve endings. 
Abbreviations: ACE, angiotensin-converting enzyme; ATiR, angiotensin (type 
1) receptor; NET, NE transporter; NHE, Na^/H^ exchanger.
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3. Functional significance of cardiac mast ceiFderived renin
3.1 Introduction
Originally identified in 1878 by Paul Ehrlich, mast cells 
characteristically contain dense cytoplasmic granules which exhibit 
metachromasia when exposed to aniline dyes (Crivellato et al., 2003). 
Resident in almost all tissues, particularly loose connective tissue surrounding 
blood vessels and nerves, mast cells are classically considered mainly as 
inflammatory cells associated with the allergic response (Prussin and 
Metcalfe, 2003). Recent studies are beginning to reveal the true 
multifunctional nature of this complex cell type. In addition to allergic, 
inflammatory and chronic disorders affecting various organs, mast cells play a 
crucial role in host defense (Henz et al., 2001), modulate coagulation 
cascades (Krishnaswamy et al., 2005), and regulate tissue fibrosis and repair 
(Puxeddu et al , 2003). In fact, there are few disease types in which mast 
cells are not at least implicated.
Mast cells arise from mast-cell-committed CD34^ precursors in the 
bone marrow, which are c-kif". These non-granulated precursor cells circulate 
in the blood and lymphatics, and upon migration into vascularized tissues, 
mast cell differentiation and maturation occur under the influence of stem cell 
factor and other locally produced cytokines (Li and Krilis, 1999). Mast cell 
activation may occur through both immune and non-immune mechanisms. 
Mast cells express a high affinity receptor for IgE (FcsRI), a receptor of such 
high affinity that binding is essentially irreversible, hence, mast cells are 
coated with IgE. Classical immunological activation as occurs in allergy is
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due to cross-bridging of IgE receptors by antigen binding, which triggers 
granule exocytosis and mediator release (Prussin and Metcalfe, 2003). Mast 
cells may also be activated to degranulate by a variety of other stimuli, 
including: polybasic molecules such as compound 48/80 (Paton, 1951), 
superoxide anion (Krishnaswamy et al., 2005), neuropeptides (substance P, 
calcitonin gene-related peptide, somatostatin, vasoactive intestinal 
polypeptide), cytokines such as stem cell factor and histamine-releasing 
factors (IL-1, -3 and -8, platelet factor 4) (Metcalfe et al., 1997) and 
components of the complement cascade (C3a, C4a and C5a) (Erdei et al., 
2004).
Diversity in mast cell function is a consequence of the vast array of 
mediators which they produce. Classically divided into three groups, these 
consist of: preformed mediators (e.g. histamine, serine proteases, 
carboxypeptidase A, and proteoglycans), newly synthesized lipid mediators 
(e.g. PGÜ2 and LTC4), and cytokines (e.g. TNF-a, interleukins and 
chemokines) (Prussin and Metcalfe, 2003).
The presence of mast cells in the human heart is well established 
(Dvorak, 1986; Marone et al., 1995). Cardiac mast cells have been linked to 
numerous cardiovascular diseases, including: myocarditis (Turlington and 
Edwards, 1988), cardiomyopathy (Patella et al., 1997 and 1998), transplant- 
related fibrosis (Li et al., 1992), ischemic heart disease (Lindstedt and 
Kovanen, 2004), myocardial infarction (Frangogiannis et al., 2002), heart 
failure (Hara et al., 2002) and hypertensive heart disease (Shiota et al., 2003).
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However, the precise role of mast cells and their mediators in the 
pathogenesis of cardiovascular disease remains largely unknown.
Based on the discovery that mast cells are a source of cardiac renin 
(Chapter 2 and Silver et al., 2004), and since mast cells are known to 
degranulate in myocardial ischemia (Kruger et al., 1990; Frangogiannis et al.,
1998), an ultimate aim was to demonstrate that mast cell-derived renin is 
functionally important in the setting of myocardial ischemia. To confirm the 
hypothesis outlined in Figure 2.12, the following points are addressed:
i) Does cardiac mast cell degranulation (by numerous means, most 
importantly ischemia-reperfusion) release significant levels of active 
renin into the coronary effluent?
ii) Does the release of mast cell-derived renin have the capacity to trigger 
cardiac renin-angiotensin system activation?
iii) Is there a positive coupling between ATi-receptor activation and the 
NaVH'" exchanger on cardiac sympathetic nerve endings, such that 
locally formed ANG II can potentiate carrier-mediated NE release and 
foster arrhythmic cardiac dysfunction?
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3.2 Methods
Perfusion of Guinea-pig hearts ex vivo. This procedure was 
conducted by Dr. Seiichiro Kano. Male Hartley guinea pigs (Charles River, 
Wilmington, MA) weighing 300-350 grams were anesthetized with CO2 and 
killed by exsanguination. Hearts were rapidly isolated and perfused at 
constant pressure (40 cm H2 O) with oxygenated Ringer’s solution at 37°C for 
30 min prior to challenge with compound 48/80, chicken ovalbumin, or 
induction of ischemia in a Langendorff apparatus (Radnoti, Monrovia, CA) 
(Imamura et al., 1996). In some cases, hearts were continuously perfused 
with pharmacologic agents (i.e., lodoxamide, BILA2157, enalaprilat, 
EXP3174) prior and during challenge with 48/80 and induction of 
ischemia/reperfusion. Normothermic 20-min global ischemia was induced by 
complete cessation of coronary perfusion, followed by 30-min reperfusion. 
Coronary flow was measured by timed collections of the effluent every 2 min; 
all samples were assayed for renin, NE and histamine. Surface ECG was 
obtained from leads attached to the left ventricle and the right atrium, 
recorded in both analog and digital format, and analyzed using Powerlab/8SP 
(AD Instruments, Colorado Springs, CO). Onset and duration of reperfusion 
arrhythmias were recorded and quantified according to the Lambeth 
Conventions (Walker et al., 1988).
Isolated guinea pig heart anaphylaxis. This procedure was 
conducted by Dr. Seiichiro Kano. Male Hartley guinea pigs were passively 
sensitized by an i.p. injection of 0.8 mg of rabbit anti-ovalbumin IgG. Twenty 
four hours later, the hearts of the sensitized guinea pigs were isolated and
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perfused as indicated above and eventually challenged by infusion into the 
aorta of 1 mg ovalbumin in warm oxygenated Ringer's solution.
RT-PCR. Total RNA was extracted from human kidney tissue and SH- 
SY5Y cells using RNA STAT-60 reagent (Tel-Test “B” Inc., TX). Total RNA (1 
pg) from each sample was reverse transcribed and assayed by PGR using 
Superscript One-Step RT-PCR System with Platinum Taq DNA Polymerase 
(Invitrogen Corp., CA). The following primers for human NHE-1 and NHE-2 
were used, as previously described (Dudeja et al., 1996; Thwaites et al.,
1999):
NHE-1: 336GACTACACACACGTGCGCACCCC3 4 8 and
sggT C C A G G A T G A T G G G C G G C A G C A G G A A G  A G G  AA537;
NHE-2: 16GAAGATGTTTGTGGACATTGGGG38 and
565CGTCTGAGCTGCTGCTATTGC545.
The cycling parameters were as follows: 94°C for 1 min, 58°C for 1 min, and 
72°C for 2 min (40 cycles). PCR products generated were 232 and 549 bp for 
NHE-1 and NHE-2, respectively. PCR products were separated on a 1% 
agarose gel and stained with ethidium bromide.
Intracellular pH and Ca^  ^ measurements in SH-SY5Y-AT ia  cells.
SH-SY5Y neuroblastoma cells stably transfected with the rat AT ia receptor 
were provided by Dr. P. F. T. Vaughan (University of Leeds, UK). SH-SY5Y- 
AT ia cells were grown to -60%  confluence (2 days after plating) on 22-mm^ 
standard glass coverslips (no. 1) and maintained in a 1:1 ratio of Ham’s F-12 
and Eagle’s MEM, supplemented with 10% FBS, 2 mM L-glutamine, 50 pg/ml 
gentamycin, 50 U/ml penicillin, and 300 pg/ml hygromycin at 37®C and 5%
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CO2 . Cells were loaded at room temperature in the incubation medium with 
the membrane-permeant forms of the pHj indicator BCECF AM (5 pM) for 20 
min or the Ca^'^-sensitive dye fura-2 AM (5 pM), for 60 min. For experiments 
where increases in intracellular Ca^  ^ (Cai^ "") were buffered, cells were loaded 
with the membrane-permeable form of BAPTA (BAPTA AM; 10 pM), for 30 
min and washed with fresh medium before cells were exposed to either 
BCECF AM or fura-2 AM. After exposure to the dyes, cells were rinsed with 
HEPES-buffered Na'^-Ringer (NaR) solution composed of (in mM) 140 NaCI, 
5.0 KCI, 10 HEPES, 2.0 CaCl2, and 1.0 MgCL, pH 7.4. The coverslip with the 
dye-loaded cells was attached to the bottom of a flow-through superfusion 
chamber and mounted on the stage of an inverted epifluorescence 
microscope (Diaphot, Nikon Inc. Instrument Group, NY). The cells in the 
chamber were superfused and maintained at 37°C, as described previously 
(Silver, 1998; Silver et al., 2001). Cells were first visualized under transmitted 
light with a Nikon CF Fluor oil immersion objective (x40/1.3 numerical 
aperture) before the start of the fluorescence measurements. For experiments 
where NHE activity was assayed as the rate of Na^-dependent alkalinization 
in response to an acute acidosis, the protocol was as shown in Figure 3.1. 
Where used, drugs were added and maintained in the superfusate from the 
NH4 CI pulse on, as indicated in Figure 3.1 B.
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Figure 3.1 Experimental protocol for NHE activity assay. Representative 
traces from individual SH-SY5Y-ATia cells showing the typical Na'^-dependent 
intracellular pH recovery response after acute exposure to an NH4CI acid 
pulse in the absence (A) and presence (B) of the NHE inhibitor El PA (10 pM). 
Briefly, cells were exposed acutely to NH4CI in the absence of extracellular 
Na ,^ after which NH4CI was removed from the superfusate (0 Na^), resulting in 
intracellular acidification. No pHj recovery occurred in the absence of 
extracellular N a \ Réintroduction of extracellular Na  ^ (NaR), resulted in a Na*- 
dependent intracellular alkalinization. The rate (slope) of the Na^-dependent 
intracellular alkalinization, calculated from the point at which recovery starts, 
as indicated by the dotted line in each trace, represents the NHE activity.
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For experiments using BCECF AM, calibration of the emitted fluorescence 
signal from each cell in the field was performed at the end of each experiment 
according to the nigericin/high-K"' method (Thomas et al., 1979) and as 
previously described (Silver, 1998; Silver et al., 2001). Briefly, nigericin, a 
KVH" exchanger, was added to the calibration solutions at a final 
concentration of 10 pM. For experiments using fura-2 AM, calibration of the 
emitted fura- 2  signal from each cell in the field was carried out in the presence 
of the Ca^  ^ ionophore ionomycin (10 pM) in the presence of a HEPES buffer 
containing either 2.6 mM Ca^'' or 10 mM EGTA, titrated to pH 7.4, as 
previously described (Silver et al., 2002). Cai^ '" levels were calculated as 
described by Grynkiewicz et al. Cells in the experimental field of view were 
analyzed singularly and independently from their neighbors.
Imaging solutions. The experimental solutions were based on the NaR 
composition described above with the following substitutions: for the NH4 CI 
solution, NaCI and KOI were replaced with 20 mM NH4 CI and 120 mM A/- 
methyl-D-glucamine (NMDG/CI); for the NaVree solution, NaCI and KCI were 
replaced with 145 mM NMDG/CI. The Na'^-free solutions were titrated to pH 
7.4 with NMDG powder. The composition of the high K"-calibration solutions 
was similar to that of NaR, except that NaCI was replaced with KCI, and 
titrated with KOH to pH 6.5 and pH 7.8, respectively, as described (Silver et 
al., 2 0 0 1 ).
Eguipment. The basic components of the imaging workstation have 
been described (Silver, 1998; Silver et al., 2001) and briefly consists of: an 
inverted epifluorescence microscope (Diaphot, Nikon Inc. Instrument Group, 
Melville, NY) equipped with a 75 W  Xenon lamp, Nikon CF Fluor x i00/1.3 NA
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oil immersion objective,, fluorescence excitation filter wheel (Metal Tek) 
coupled to an additional filter wheel (Metal Tek, Morrisville, NC) holding a 
variety of neutral density filters, computer controllable excitation light shutter, 
and a cooled CCD camera (Princeton Scientific Instruments Inc., Monmouth 
Junction, NJ). The workstation was controlled with the MetaFluor software 
package (Universal Imaging; Westchester, PA). Quantitative image pairs at 
340- and 380-nm excitation with emission at 510 nm (fura-2) were obtained 
either every 15 s or every 1.0 s immediately before and during ANG II addition 
to the superfusate, or at 490- and 440-nm excitation with emission at 520 nm 
(BCECF) obtained every 15 s. The fluorescence excitation was shuttered off 
except during the brief intervals required to record image pairs.
[^H]IVIPP^ release assay. [^HjMPP^ was used in release experiments 
because it is regarded as an optimal NE transporter substrate (Smith and 
Levi, 1999). SH-SY5Y-AT ia cells were grown for 7 days in 24-well culture 
plates. Cells were rinsed with 0.45 ml HEPES-buffered NaR solution. Next, 
cells were loaded by incubation for 60 min in 0.23 ml NaR solution containing 
20 nM [^HjMPP''. After incubation, cells were rinsed twice and treated for 20 
min with the appropriate drugs El PA, 1 pM, an inhibitor of NHE; DMI, 1 pM, a 
blocker of the NE transporter; EXP3174, 300 nM, an ATi-receptor antagonist; 
cariporide, 1 pM, a selective inhibitor of the NHE-1 isoform; and BAPTA-AM, 
10 pM, a Ca^ "" chelator] before the release assay. Release of [^H]MPP^ in the 
presence of the aforementioned drugs was then initiated by the addition of 
NaR solution (0.45 ml) in the absence and presence of ANG II (100 nM). 
Aliquots (0.3 ml) of release buffer were taken from each well following 10 min 
incubation, and the remaining buffer was immediately aspirated. The release
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buffer aliquots were transferred to scintillation vials containing 3.5 ml of 
scintillation cocktail and were counted for 3 min in a liquid scintillation counter 
(Beckman LS6000). Finally, the cells were lysed with 0.45 ml of 0.3% Triton 
X-100 for 30 min. Aliquots of lysate were also counted, enabling pH] release 
to be calculated as a percentage of the total pH] cell content.
Perfusion of mouse hearts ex vivo. This procedure was conducted 
by Dr. Ulrich Schaefer. Mast cell-deficient, c-kit-null WBB6 Fi-WAAA and their 
congenic controls W BB6F1-Y, weighing 20-30g, were purchased from 
Jackson Laboratory, Bar Harbor, ME. Following pre-treatment with heparin 
(100 I.U. i.p.) mice were anesthetized with CO2 and killed by cervical 
dislocation. Hearts were quickly excised and cooled in ice-cold Krebs- 
Henseleit (KH) solution containing pyruvic acid (0.5 mM) and equilibrated with 
9 5 % O2 + 5 % CO2 , as previously described (Koyama et al., 2003a). The aorta 
was cannulated with an 18-gauge custom-made steel cannula, and the heart 
was perfused in a Langendorff apparatus (see above) (pressure: 100 cm H2 O) 
with KH buffer at 37°C. Coronary flow was measured by timed collections of 
the effluent every 5 min; all samples were assayed for renin, NE and 
histamine. Following stabilization, global ischemia was induced by 30-min 
stop-flow, followed by 30-min reperfusion.
Immunohistochemistry of cardiac mast cells. Cryostat sections (10 
pm) of paraformaldehyde (PF)-fixed heart from either congenic control or c- 
kit-null mice were triple-stained with a rabbit polyclonal renin antibody, FITC- 
avidin to identify mast cells, and DAP I to visualize nuclei. Briefly, sections 
from congenic control or c-kit-null mouse hearts were rinsed in PBS and then
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permeabilized for 10 min at 37°C with a solution containing 4% FBS and 0.3% 
Triton X-100 dissolved in PBS. After rinsing the sections with PBS, 10% FBS 
was applied to the sections for 1.5 h at 37°C to minimize non-specific binding, 
prior to addition of antibodies. The polyclonal anti-renin antibody (1:400) was 
applied to the sections for 2 h at 37°C, followed by three washes in PBS. 
Next, sections were exposed to Alexa Fluor 594 donkey anti-rabbit IgG (red) 
(1:1,100) and FITC-avidin (green) (1:1,300) for 1 h at 37°C. Following three 
washes in PBS, the sections were incubated with a 1:10,000 dilution of DAP I 
(blue) for 3 min at room temperature. Sections were washed in PBS, followed 
by fixation for 3 min with 4% PF. After another PBS wash, the sections were 
mounted in Vectashield anti-fading solution (Vector Laboratories, Burlingame, 
CA). Mast cells were identified as cells that were triple-stained (i.e., renin-, 
FITC-avidin-, and DAPI-positive). For both congenic control and c-kit-null 
mice, multiple complete heart sections were screened. The rabbit polyclonal 
ànti-renin antibody was kindly provided by Dr. Daniel F. Catanzaro (Weill- 
Cornell Medical Center). FITC-avidin and DAPI were purchased from Vector 
Laboratories (Burlingame, CA) and Molecular Probes (Eugene, OR), 
respectively. Heart sections were examined with an inverted epifluorescence 
microscope (Nikon Eclipse TE 2000-U, Melville, NY) interfaced to an electron 
multiplying-charged-coupled device (Hamamatsu, Bridgewater, NJ) and 
processed with Metamorph software (Universal Imaging, Downingtown, PA).
Norepinephrine assay. Coronary effluent and synaptosomal 
supernatant were assayed for NE by HPLC with electrochemical detection as 
described in Chapter 2.
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Renin Assay. Coronary effluent was immediately concentrated 6  to 8  
fold by centrifugal filtration (Millipore, Bedford, MA). Concentrated samples 
were incubated overnight with human or porcine angiotensinogen (240 nM) 
for guinea pig and mouse experiments, respectively. Subsequently, renin 
activity (ANG I formed) was determined in these samples using a 
GammaCoat Plasma Renin Activity ^^ 1^ Radioimmunoassay kit (DiaSorin, 
Stillwater, MN). The detection limit was ~0.01 pmol ANG I.
Histamine Assay. Coronary effluent was assayed for histamine 
content with the use of a commercial enzyme immunoassay kit (Immunotech 
International, Westbrook, ME) (Hatta et al., 1997). The recovery of histamine 
was - 1 0 0 %, and the detection limit was - 0 . 0 2  pmol.
Drugs and Chemicals. Cariporide was kindly provided by Prof. B. A. 
Schoelkens (Hoechst; Frankfurt am Main, Germany). BILA2157 was a gift 
from Boehringer Ingelheim (Canada) Ltd. Enalaprilat and EXP3174 were a 
gift from Merck Sharpe & Dohme Research Laboratories (West Point, PA). 
Lodoxamide was a gift from Dr. B.R. Lucchesi, University of Michigan. 
Human and porcine plasma angiotensinogen was purchased from 
Calbiochem (La Jolla, CA) and Sigma-Aldrich Co. (St Louis, MO), 
respectively. Compound 48/80 and all other drugs and chemicals were 
purchased from Sigma-Aldrich (St Louis, MO).
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3.3 Results
Detection of mast cell-derived renin in guinea pig coronary effluent
In order to test the feasibility of measuring renin activity in the coronary 
effluent of ex vivo, Langendorff-perfused guinea-pig hearts, initial experiments 
involved challenging hearts immunologically. Spontaneously beating hearts, 
isolated from passively presensitized guinea pigs, were challenged with 
antigen. These hearts exhibited a typical anaphylactic response, 
characterized by tachycardia, arrhythmias and coronary vasoconstriction 
(Rubin and Levi, 1995). Coronary effluent was collected and assayed for 
histamine and ANG l-forming activity. Indicative of mast cell degranulation, 
there was a considerable release of histamine into the coronary effluent (-7  
nmol/g) within two minutes of antigen administration (Figure 3.2A). The 
profile of ANG l-forming activity in the coronary effluent was superimposable 
to that of histamine (Figure 3.2B). In fact, there is a positive correlation 
between the coronary overflow of histamine and ANG l-forming activity 
(Figure 3.2C). Since renin is likely to be the major source of ANG I in the 
effluent (as observed in HMC-1 releasate), this further strengthens the finding 
that mast cells are a source of cardiac renin.
Cardiac mast cell degranulation was also stimulated chemically with 
the classical mast cell degranulating agent 48/80 (Levi and Allan, 1980). 
Coronary effluent was collected and histamine overflow assayed as a positive 
marker of mast cell degranulation. Indeed, coronary histamine overflow 
increased from a non-measurable level to -4  nmol/g upon challenge with 
48/80 (300 pg bolus) (Figure 3.3A). Correspondingly, mast cell degranulation 
resulted in a -4-fold increase in ANG l-forming activity in the coronary
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effluent, above baseline. This increase in ANG l-forming activity could be 
abolished by pre-treating hearts with the renin-specific inhibitor BILA2157 
(100 nM) prior to challenge with 48/80, thus implicating renin as the major 
source of ANG I measured in the coronary effluent (Figure 3.3B). Histamine 
overflow was not significantly reduced by the presence of BILA2157, 
confirming selectivity of BILA2157 for renin inhibition.
Coupling of ATi-receptors to NHE activity and carrier-mediated NE 
reiease
Having established that degranulation of cardiac mast cells releases 
considerable levels of active renin which could drive local ANG II formation, 
and with the knowledge that ANG II stimulates NHE activity in myocytes 
(Gunasegaram et al., 1999; Karmazyn et al., 1999), whether ANG II could 
also stimulate neuronal NHE activity was next investigated. The pivotal step 
driving carrier-mediated NE release is intraneuronal Na" accumulation, a 
consequence of increased NHE activity. Therefore, a coupling of ATi- 
receptors to NHE in cardiac sympathetic nerves may well drive carrier- 
mediated NE release;
The human neuroblastoma cell line SH-SY5Y is considered an optimal 
model of sympathetic nerve endings (Vaughan et al., 1995). NHE-1 is 
considered a ubiquitous protein (Slepkov and Fliegel, 2002). Nonetheless, 
RT-PCR was performed on total RNA extracted from SH-SY5Y cells using 
primers specific for human NHE isoforms 1 and 2. Whole human kidney, 
known to express both NHE isoforms (Tse et al., 1993), was run as a positive 
control. Indeed, SH-SY5Y cells were found to express both NHE isoforms 1
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and 2 (Figure 3.4A). Accordingly for ATi-receptor-NHE coupling studies, SH- 
SY5Y cells stably transfected with recombinant ATiA-receptor, SH-SY5Y-ATia 
cells (McDonald et al., 1995) were utilized. These cells were exposed to an 
acute NH4 CI acid pulse and the rate of Na"-dependent intracellular pH (pHJ 
recovery (NHE activity) was assayed (see Methods, Figure 3.1 for protocol). 
Typically, the initial pHj of SH-SY5Y-AT1A cells was -6 .7  and removal of NH4 CI 
in the absence of extracellular Na" resulted in an intracellular acidification of 
-0 .4  pH units to -6 .3 . In the absence of extracellular Na" there was no 
recovery of the intracellular pH, however, addition of Na" resulted in 
intracellular alkalinization back to a pH of - 6 .6 . The rate of this Na"- 
dependent pHi recovery was -0 .03  pH units/min (see Methods, Figure 3.1 A 
and Results, Figure 3.4B). The role of NHE in the Na"-dependent pH| 
recovery was established using a specific NHE inhibitor, El PA (10 pM), which 
blocked the pHi recovery at pH -6 .4  (see Methods, Figure 3.1 B). However, at 
this concentration, El PA cannot be used to determine which NHE isoform was 
responsible for the Na"-dependent pHj recovery (Masereel et al., 2003). In 
contrast to El PA, addition of ANG II (100 nM) doubled the rate of Na"- 
dependent pHj recovery compared to that seen in control cells (Figure 3.4B). 
To test which NHE isoform was mediating this ANG ll-induced increase in 
Na"-dependent pHj recovery in the SH-SY5Y-AT1A cells, the selective NHE-1 
inhibitor cariporide was utilized (1 pM; IC5o ~ 2  and 30 pM for NHE-1 and -2, 
respectively) (Mentzer, Jr. et al., 2003). Cariporide (1 pM) in the presence of 
ANG II (100 nM), completely inhibited the rate of Na"-dependent pHj recovery 
to a level below that of control (Figure 3.4B), indicating that NHE-1 is the 
isoform responsible for pHj recovery in these cells under the experimental
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conditions used. To establish that the ANG ll-induced stimulation of NHE-1 
activity was indeed an ATi-receptor mediated effect, Na"-dependent pHj 
recoveries were recorded from SH-SY5Y-AT ia cells exposed to ANG II (100 
nM) in the presence of the ATi-receptor antagonist EXP3174 (300 nM), the 
active metabolite of losartan (Wong et al., 1990; Wienen et al., 1992). 
Blockade of ATi-receptors totally prevented the ANG ll-induced stimulation of 
NHE-1 activity, restoring it to a level comparable to control cells (Figure 3.4B).
Others have shown that ATi-receptor activation is associated with 
transient increases in intracellular Ca^" (Ca^"i) and consequently increased 
exocytosis in SH-SY5Y-ATia cells (McDonald et al., 1995). Individual fura-2- 
loaded SH-SY5Y-ATia cells were monitiored, acute exposure to ANG II (100 
nM) evoked a rapid and transient increase in Ca^" from a baseline of -100  
nM to a peak of -220  nM, which then returned to baseline. A representative 
trace from a single cell is shown in Figure 3.4C {top). It was questioned 
whether this ANG ll-induced Ca^" transient might be involved in the ANG II- 
mediated stimulation of NHE activity. To test this possibility cells were treated 
with the membrane-permeable form of the Ca^" chelator BAPTA (10 pM) prior 
to loading with fura-2 AM. This approach was very effective at blocking the 
ANG ll-associated Ca^" transient without affecting the baseline Ca^" level 
(Figure 3.4C, bottom). Cells treated with BAPTA AM (10 pM) prior to loading 
with BCECF AM, and then subsequently exposed to the NH4 CI acid pulse 
protocol in the presence of ANG II (100 nM), exhibited NHE activities which 
were very similar to control cells (Figure 3.4B). These data suggest that ANG 
ll-evoked stimulation of NHE-1 via ATi-receptors is a Ca^"-dependent 
process.
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To investigate a link between ATi-receptors, NHE-1 and carrier- 
mediated release in SH-SY5Y-AT1A cells, cells were preloaded with tritiated N- 
methyl-4-phenylpyridinium ([^H]MPP"), an optimal substrate of the NE 
transporter (Smith and Levi, 1999). Ten minutes exposure of pH]MPP"- 
loaded cells to ANG II (100 nM) triggered an -25%  increase in [^H]MPP" 
release relative to control cells (Figure 3.5). This ANG ll-induced release of 
pH]MPP" was characteristic of carrier-mediated release since it could be 
prevented by pre-exposing the cells to the NHE inhibitor El PA (1 pM), the 
NHE-1 inhibitor cariporide (1 pM), or the NE transporter inhibitor desipramine 
(DMI; 1 pM) prior to ANG II treatment (Figure 3.5). Pretreatment of the cells 
with the ATi-receptor antagonist EXP3174 (300 nM) or the membrane 
permeable Ca^" chelator BAPTA also blocked the ANG ll-induced carrier- 
mediated [^H]MPP" release (Figure 3.5). Collectively, these data demonstrate 
a clear link between ATi-receptor activation and stimulation of carrier- 
mediated release which involves a Ca^Vdependent increase in NHE-1 
activity.
Ischemia-reperfusion-induced release of mast cell-derived renin, NE 
overflow and reperfusion arrhythmias in guinea pig hearts
Having determined that the activity of mast cell-derived renin could be 
assayed in the coronary effluent of guinea pig hearts and demonstrated that 
ATi-receptor activation is indeed coupled to carrier-mediated release via NHE 
activation in a neuronal cell model, the functional significance of cardiac mast 
cell-derived renin in myocardial ischemia was investigated. Ex vivo, 
Langendorff-perfused guinea-pig hearts were subjected to 20-min stop-flow
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global ischemia, followed by 30-min reperfusion (Hatta et al., 1999). ANG I- 
forming activity during reperfusion was - 1 5-fold greater than pre-ischemia 
(Figure 3.6C), whilst NE overflow increased -80-fold (Figure 3.6B). The 
reperfusion period was also associated with ventricular arrhythmias (e.g. 
tachycardia (VT) and fibrillation (VF)); these rhythm disturbances lasted an 
average of -300  seconds (Figure 3.6A). The results suggest that ischemia- 
reperfusion triggers renin release from cardiac mast cells. Indeed, the mast 
cell stabilizers lodoxamide (10 pM) and cromolyn (300 pM) attenuated not 
only ANG l-forming activity in the coronary effluent during reperfusion (by 
-60% ), but also NE overflow (by -40% ) and associated ventricular 
arrhythmias (by -85% ) (Figures 3.6 A, B and 3.7). Furthermore, in hearts 
perfused with the renin-specific inhibitor BILA2157 (100 nM), ANG l-forming 
activity in the coronary effluent during reperfusion was markedly diminished 
by -95% , to a level not significantly different from pre-ischemia (Figure 3.6C). 
The ATi-receptor antagonist EXP3174 (300 nM) had no effect upon coronary 
ANG l-forming activity during reperfusion, consistent with its action being 
downstream of renin at the ANG II receptor level (Figure 3.6C). However, 
similar to mast cell stabilization, both inhibition of renin activity and ATi- 
receptor blockade were associated with a significant decrease in both NE 
overflow (-65% ) and ventricular arrhythmias (-85% ) (Figures 3.6 A, B and 
3.7). Importantly, mast cell stabilization, renin inhibition and ATi-receptor 
blockade not only decrease the average duration of ventricular arrhythmias, in 
fact they significantly reduce the incidence, as shown in Figure 3.7A. 
Collectively these data suggest that mast cells are a significant source of
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cardiac renin capable of driving local ANG II formation which ultimately 
exacerbates NE release and associated arrhythmias.
Ischemia-reperfusion in mast cell-deficient mouse hearts: lack of renin- 
stimulated NE release
c-kit-null (KO) mice have a profound deficiency in mast cells (less than 
1% of their congenital wild type littermates (WT) in both peritoneum and skin) 
(Kitamura et al., 1978). A number of earlier investigations have shown these 
mice to be a valuable tool for determination of mast cell functions in vivo 
(Tang et al., 1998; Ramos et al., 1992; Zhang et al., 1992; Ramos et al., 1990 
and 1991; Wershil et al., 1988). It was reasoned that ischemia-reperfusion 
experiments in the hearts of these mice should provide conclusive evidence 
regarding the role of mast cells in ischemia-induced activation of the cardiac 
renin-angiotensin system.
Initially, frozen sections from c-kit-null and congenic control mouse 
hearts were screened for the presence of mast cells using conjugated avidin, 
which selectively stains mast cell granules (Tharp et al., 1985), and the 
polyclonal BRI renin antibody. Figure 3.8 shows representative images of 
sections from c-kit-null and congenic control mouse hearts. No mast cells 
were observed in any of the c-kit-null mouse heart sections screened, 
confirming their mast-cell-deficient phenotype. The avidin-positive mast cell 
population observed in congenic control heart sections was also 
immunopositive for renin. No other cell types were stained with either the 
conjugated avidin or the renin antibody.
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Similar to previous experiments in guinea-pig hearts, ex vivo 
Langendorff-perfused mast-cell-deficient and congenic control mouse hearts 
were subjected to 30-min stop-flow global ischemia followed by 30-min 
reperfusion. Histamine, renin and NE were assayed in the coronary effluent 
during reperfusion. Indicative of mast cell degranulation, coronary overflow of 
histamine increased - 2 2 -fold above pre-ischemic levels in congenic control 
mouse hearts. Conversely, histamine overflow from c-kit null mice was 
minimal ( - 2 -fold increase), in agreement with a lack of mast cells in the hearts 
of these mice (Figure 3.10). Reperfusion of congenic control mouse hearts 
was also associated with a substantial increase in coronary ANG l-forming 
activity, from a non-measurable level pre-ischemia to -7 0  pg/g/hr. In contrast, 
the coronary ANG l-forming activity from c-kit-null mice during reperfusion 
was not significantly different from zero (Figure 3.9), supportive of mast cells 
being pivotal for cardiac renin-angiotensin system activation. Most 
interestingly, NE overflow during reperfusion increased -42-fold in congenic 
control hearts, compared to only - 8 -fold in c-kit-null mice (Figure 3 .IOC). 
Moreover, if congenic control hearts were subjected to ischemia-reperfusion 
in the presence of the renin inhibitor BILA2157 (100 nM), the increase in NE 
overflow became more similar to that of the c-kit-null hearts (-7-fold as 
compared to the -42-fold increase observed in the absence of renin 
inhibition). The small increase in NE overflow observed in c-kit-null mice was 
unaffected by renin inhibition, further indicative of mast cells as the primary 
source of cardiac renin (Figure 3.10D). Histamine overflow from congenic 
control hearts was unaffected by renin inhibition (Figure 3.1 OB), ruling out any 
possible negative effect of BILA2157 upon mast cell degranulation. These
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observations highlight the critical role of mast-cell-derived renin in activating 
the cardiac renin-angiotensin system, which ultimately drives excessive NE 
release.
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Figure 3.2 Immunological challenge of cardiac mast cells results In 
overflow of histamine and ANG l-forming activity Into the coronary 
effluent. Coronary overflow of ANG l-forming activity (i.e. ANG I formed in 
samples of coronary effluent incubated with human angiotensinogen, see 
Methods) and histamine from pre-sensitized Langendorff-perfused guinea-pig 
hearts challenged with antigen. Bars are means (± SEM; n = 11). 0 min 
values indicate pre-antigen and 2, 4 and 6  minute effluent collections are 
following antigen administration. Panel C: Positive correlation between 
coronary histamine and ANG l-forming activity following cardiac anaphylaxis 
(P<0.05; n=11).
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Figure 3.3 Chemical chalienge of cardiac mast celis results in histamine 
and renin overflow into the coronary effluent. Coronary overflow of active 
renin (i.e. ANG I formed in samples of coronary effluent incubated with human 
angiotensinogen, see Methods) and histamine from Langendorff-perfused 
guinea-pig hearts challenged with the mast-cell degranulating compound 
48/80 (300 pg bolus), either in the absence (Cont) or presence of the renin 
inhibitor BILA2157 (100 nM; BILA). Bars are means (± SEM; panel A: n = 7, 4 
and 3, respectively; panel B: n = 6, 3 and 3, respectively). Basal values 
indicate pre-48/80. Panel B: *, p<0.05 from both basal and BI LA-treated (by 
one-way AN OVA with Dunnett’s post test); neither basal nor BI LA-treated are 
significantly different from zero (one-sample t-test).
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Figure 3.4 ANG II stimulates NHE-1 activity in SH-SY5Y-ATia cells via a 
Ca^*-dependent pathway. A. Total RNA was extracted from SH-SY5Y cells 
and human kidney and reverse transcribed. cDNA was amplified by PCR 
using NHE-1 and -2-specific primers (lanes indicated as 1 and 2, 
respectively). Markers at 100 bp increments are shown. B. Bar graph 
comparing NHE activities measured in control SH-SY5Y-ATia cells (n=202 
cells; 5 coverslips), in cells acutely exposed to ANG II (100 nM) (n=329 cells; 
11 coverslips), and in cells acutely exposed to ANG II (100 nM) in the 
presence of either the NHE-1 inhibitor cariporide (1 pM) (n=202 cells; 4 
coverslips), the ATrreceptor antagonist EXP3174 (300 nM) (n=147 cells; 4 
coverslips), or preloaded with the Ca^  ^buffer BAPTA prior to ANG II exposure 
(n=131; 3 coverslips). Bars are means ± SEM. tP<0.05 vs. control, *P<0.05 
vs. ANG II, by one-way ANOVA followed by Tu key multiple comparison test. 
C. Representative traces depicting the acute effect of ANG II (100 nM) on 
intracellular Ca^  ^ in an individual control SH-SY5Y-ATia cell (top) and an 
individual SH-SY5Y-ATia cell loaded with the membrane-permeable form of 
the Ca^  ^ buffer BAPTA prior to ANG II exposure (bottom).
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Figure 3.5 Coupling of the ATi-receptor to NHE-1 triggers carrier- 
mediated release from SH-SY5Y-ATia ceils. ANG II (100 nM) evokes 
carrier-mediated release of [^H]MPP^ from SH-SY5Y-ATia cells (n=19 wells). 
In cells pretreated with the NE transporter inhibitor desipramine (DMI; 1 pM; 
n=6 wells), the amiloride derivative El PA (1 pM; n=4 wells), the NHE-1 
inhibitor cariporide (1 pM; n=21 wells), or preloaded with the Ca^^ buffer 
BAPTA (10 pM; n=5 wells), ANG ll-stimulated carrier-mediated [^H]MPP^ 
release was abolished. Bars are means ± SEM. *P<0.05 vs. control, by one­
way ANOVA followed by Tu key multiple comparison test.
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Figure 3.6 Ischemia-reperfusion causes the release of active renin 
(expressed as ANG I formed; panel C) and NE (Panel B), and elicits 
arrhythmias in guinea-pig hearts perfused ex vivo in a Langendorff 
apparatus (Panel A). Fifty five hearts were subjected to 20-min global 
ischemia followed by 30-min reperfusion either in the absence (control; n=15) 
or presence of lodoxamide (10 pM; n=13), cromolyn (300 pM; n=11), BILA 
2157 (100 nM; n=6) or EXP3174 (300 nM; n=10). Bars are means ±SEM. 
Panel A: duration of reperfusion arrhythmias (i.e., ventricular tachycardia and 
fibrillation). Panels B and C: total overflow of NE and renin, respectively. *, 
significantly different (p<0.05) from own control by one-way ANOVA with 
Dunnett’s post test.
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Figure 3.7 Pharmacological mast ceil stabilization, renin inhibition and 
ATi-receptor blockade prevent ventricular fibrillation in a guinea-pig 
heart model of ischemia-reperfusion. A. Percent incidence of VTA/F in 
fifty five hearts subjected to 20-min global ischemia followed by 30-min 
reperfusion either in the absence (control; n=15) or presence of lodoxamide 
(10 pM; n=13), cromolyn (300 pM; n=11), BILA2157 (100 nM; n=6) or 
EXP3174 (300 nM; n=10). B. Representative EGG tracings from five isolated 
guinea-pig hearts subjected to 20-min stop-flow global ischemia followed by 
30-min reperfusion in the presence or absence of lodoxamide (10 pM), 
cromolyn (300 pM), BILA2157 (100 nM) or EXP3174 (300 nM).
8 3
Thesis Christina J. Mackins
congenic control c-kit-null
Figure 3.8 identification of renin-positive mast ceiis in mouse heart 
sections. A: Representative section of congenic control mouse heart 
stained with the polyclonal renin antibody (red), FITC-avidin (green) to identify 
mast cells, and DAPI (blue) to visualize nuclei. B: Section of c-kit-null mouse 
heart stained with the polyclonal renin antibody, FITC-avidin and DAPI. No 
mast cells were detected in any of the c-kit-null mouse heart sections 
screened. (A and B viewed with a x60 objective). Scale bars, 10 pm.
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Figure 3.9 ANG [-forming activity in the coronary overfiow of congenic 
controi (CC) and c-kit-nuii (KO) isoiated mouse hearts. Hearts were 
subjected to stop-flow ischemia for 30 min followed by 30-min reperfusion. 
There was no measurable ANG l-forming activity in the effluent of any heart in 
the pre-ischemic period; ANG l-forming activity released from the KO hearts 
was not significantly different from zero (one-sample t-test), but significantly 
different from CC hearts (p<0.05, by unpaired Student’s t-test). Bars are 
means ± SEM (n = 6 and 9, for CC and KO, respectively).
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Figure 3.10 Coronary overfiow of NE and histamine during reperfusion 
of congenic controi (CC) and c-kit-nuii (KO) mouse hearts. Hearts were 
subjected to 30-minute stop-flow global ischemia. Hearts were either 
untreated (Control; n= 9+9) or treated with the renin inhibitor BILA2157 (100 
nM; n= 5+5). Bars represent mean fold increases ± SEM. *, indicates a 
significant difference (p<0.05) between KO and CC within each panel by 
unpaired Student’s t-test. Pre-ischemia overflow values were (pmol/g): panel 
A, WT 6.15 ± 1.07 and KO 3.56 ± 0.56; panel B, WT 29.04 ± 14.48 and KO 
3.30 ± 0.79; panel C, WT 1.42 ± 0.33 and KO 2.31 ± 0.62; panel D, WT 1.46 ± 
0.53 and KO 0.58 ± 0.06.
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3.4 Discussion
In view of previous findings that mast cells are a source of active renin 
and that renin-positive mast cells are found juxtaposed to nerve endings in the 
heart (Chapter 2 and Silver et al., 2004), evidence was sought in support of 
the hypothesis that mast cell degranulation associated with myocardial 
ischemia may be a pivotal step in cardiac renin-angiotensin system activation, 
leading to local ANG II formation, ATi-receptor activation on cSNE, enhanced 
NE release and cardiac dysfunction. In fact, an editorial article challenged us 
to determine the physiological importance of renin production by cardiac mast 
cells (Xiao and Bernstein, 2005).
In as much as anaphylaxis is characterized by a sudden massive 
release of mast cell mediators (Kemp and Lockey, 2002), an ex vivo, 
Langendorff-perfused guinea-pig heart model of cardiac anaphylaxis (Rubin 
and Levi, 1995) was utilized to determine the feasibility of measuring the 
release of mast cell-derived ANG l-forming activity into the coronary effluent. 
Indeed, within two minutes of antigen challenge in passively sensitized hearts, 
there was a considerable coronary overflow not only of histamine, the 
classical marker of mast cell degranulation, but also of ANG l-forming activity 
(Figure 3.2A and B). In fact, a positive correlation between the coronary 
overflow levels of histamine and ANG l-forming activity was observed (Figure 
3.2C), further strengthening the hypothesis that mast cell degranulation may 
represent a pivotal step in renin-angiotensin system activation in the heart. 
Langendorff-perfused guinea-pig hearts were also chemically challenged 
using the potent mast cell degranulating substance compound 48/80 (Paton,
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1951). As observed in immunologically challenged hearts, administration of 
48/80 resulted in the coronary overflow of both histamine and ANG l-forming 
activity (Figure 3.3). Most importantly, overflow of 48/80-induced ANG I 
forming activity was abolished in hearts perfused with the renin-specific 
inhibitor BILA2157 (Figure 3.3B), implicating renin as the major source of 
mast cell-derived coronary ANG I.
Having determined that cardiac mast cell degranulation is associated 
with an appreciable release of active renin which can indeed be measured in 
the coronary effluent (ANG I formation), the question of events occurring 
downstream of ANG I formation was addressed. Like angiotensinogen, ACE 
is also known to be present in the cardiac interstitium (de Lannoy et al., 2001), 
therefore it is conceivable that mast cell-derived renin is capable of driving 
ANG II formation. Indeed, myocardial ischemia is associated with enhanced 
local ANG II production (lhara et al., 2000; Jalowy et al., 1999). Furthermore, 
it was previously shown that renin derived from mast cells contaminating the 
cardiac synaptosomal preparation is capable of driving ANG II formation 
which leads to an increased angiotensinogen-dependent NE release, an 
effect which could be prevented by selective inhibition of the renin- 
angiotensin-system at the levels of: renin, ACE and ATi-receptors (Figure 
2.10). Therefore, it was postulated that local ANG II may stimulate NHE 
activity in cSNE, as occurs in cardiac myocytes (Gunasegaram et al., 1999; 
Karmazyn et al., 1999). Since NHE activation is the pivotal trigger for carrier- 
mediated NE release (Schomig, 1990; Kurz et al., 1995; Levi and Smith, 
2000), a coupling of ATi-receptors to NHE in cSNE is likely to drive carrier- 
mediated NE release.
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A human neuroblastoma cell line stably transfected with the 
recombinant ATiA-receptor, SH-SY5Y-AT ia (McDonald et al., 1995) and 
regarded an optimal model of sympathetic nerve endings (Vaughan et al., 
1995) was employed to investigate neuronal ATi-receptor-NHE coupling. 
Since myocardial ischemia is characterized by local acidosis (Schomig et al., 
1987; Airaksinen, 1999), SH-SY5Y-ATia cells were exposed to an acute acid 
pulse and the Na'^-dependent pHi recovery assayed as a measure of NHE 
activity. ANG II significantly enhanced NHE activity in response to acidosis, 
an effect which was abolished in the presence of cariporide, a selective NHE- 
1 antagonist, or EXP3174, an ATi-receptor blocker (Figure 3.4B). Hence, in 
SH-SY5Y-AT ia cells ATi-receptors are positively coupled to NHE-1 activity 
and this coupling is capable of triggering carrier-mediated release in cells pre- 
loaded with [^HjMPP"  ^(Figure 3.5).
Our laboratory has previously shown that ATi-receptor activation in 
depolarized cSNE leads to enhanced NE exocytosis (Seyedi et al., 1997). 
This can likely be attributed to the Caj ’^" transient observed upon exposure of 
SH-SY5Y-ATia cells to ANG II in the absence of depolarization (McDonald et 
al., 1995). The ANG ll-induced Cai^  ^ transient is a consequence of ATi- 
receptor signaling via a phospholipase C pathway, in which the secondary 
messengers inositol triphosphate (IP3) and diacylglycerol (DAG) stimulate 
release of Ca^" from intracellular stores and activate PKC, respectively (Berry 
et al., 2001). Interestingly, the coupling of ATi-receptors to NHE is also Ca '^"- 
dependent in that ANG ll-induced NHE stimulation and associated carrier- 
mediated release can both be prevented by buffering the ANG ll-induced 
Cai^ "^  transient (Figures 3.4C and 3.5). There are two potential candidates for
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this Ca^^-dependent stimulation of NHE. PKC may directly phosphorylate 
NHE at a known consensus site in its C-terminal cytoplasmic domain, 
however evidence for such an interaction has not yet been demonstrated 
(Putney et al., 2002). More likely, NHE is activated by a Ca^^-calmodulin 
complex, which involves conformational changes in the C-terminus of the 
exchanger that occur independently of phosphorylation (Bertrand et al., 1994).
The mechanisms by which ANG II stimulates NE release from cSNE 
are summarized in Figure 3.11.
Sympathetic nerve ending
EXOCYTOTIC
RELEASE
CARRIER-MEDIATED
RELEASE
ANG
NE
t  Free 
NE /
Na
ME
NE
Figure 3.11 ATi-receptor activation on cSNE stimulates Ca^^-dependent 
exocytotic and carrier-mediated ME release. Abbreviations: ATiR, 
angiotensin (type 1) receptor; NET, NE transporter; NHE, Na^/H^ exchanger.
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With knowledge that ATi-receptor activation is positively coupled to 
NHE activity and consequently carrier-mediated NE release, and having 
previously seen that mast cell-derived renin is capable of driving ANG II 
formation leading to the potentiation of NE release from cSNE, it was 
assessed whether, via a similar mechanism, mast cell-derived renin may play 
a significant role in myocardial ischemia. In ex vivo, Langendorff-perfused 
guinea-pig hearts subjected to 20-min stop-flow global ischemia, reperfusion 
was associated with a significant overflow of ANG l-forming activity and NE, 
and with the development of reperfusion arrhythmias, such as ventricular 
tachycardia and fibrillation (Figure 3.6 and 3.7). That renin was the major 
source of coronary ANG l-forming activity was confirmed using the specific 
renin inhibitor BILA2157. Importantly, mast cell stabilization with either 
lodoxamide or cromolyn was also associated with a decrease in the overflow 
of active renin. This suggests rapid mast cell degranulation and renin release 
following myocardial ischemia. Indeed mast cell degranulation is known to 
occur in myocardial ischemia and it is possible that 05a, adenosine and 
reactive oxygen species may represent the stimuli responsible (Kruger et al., 
1990; Frahgogiannis et al., 1998 and 2002). Overflow of active renin was 
unaffected in hearts treated with the ATi-receptor antagonist EXP3174, 
consistent with this compound acting downstream of renin. Mast cell 
stabilization, renin inhibition and ATi-receptor blockade each significantly 
decreased NE overflow as well as the incidence and duration of reperfusion 
arrhythmias (Figures 3.6A, B and 3.7). These findings suggest that mast cell- 
derived renin is capable of driving local ANG II formation which ultimately 
exacerbates NE release and associated arrhythmias. Indeed, it is possible
91
_____________     Christina J. Mackins
that ANG II could contribute to reperfusion arrhythmias not only by facilitating 
NE release (Seyedi et al., 1997; Zimmerman, 1962; Rump et al., 1994), but 
also by a direct arrhythmogenic action (Fleetwood et al., 1991; Rubart and 
Zipes, 2005). In patients with left-ventricular dysfunction inhibition of the 
cardiac renin-angiotensin system by means of pharmacologic inhibition of 
ACE and/or ATi-receptor blockade is associated with a reduction of 
cardiovascular morbidity and mortality (Pfeffer et al., 1992 and 2003; The 
SOLVD Investigators, 1992; Cohn and Tognoni, 2001). Whether the reduced 
mortality results, at least in part, from a decrease in the incidence of death 
from arrhythmias was not demonstrated (Rubart and Zipes, 2005). Based on 
the ex vivo studies presented herein, one would be inclined to believe that 
cardiac renin-angiotensin system blockade would reduce mortality by 
significantly decreasing the incidence of arrhythmias induced both by NÈ 
release and by a direct effect of ANG II.
With evidence to suggest that mast cells are a major source of cardiac 
renin responsible for local renin-angiotensin system activation in myocardial 
ischemia, the hypothesis was further verified in mast cell-deficient mouse 
hearts and their congenic controls (KItamura et al., 1978). It was reasoned 
that in the absence of mast cells there would be no local ischemia-induced 
renin-angiotensin system activation and therefore, NE overflow during 
reperfusion would be significantly reduced. In fact, these experiments 
showed this to be the case. Whilst coronary histamine overflow, which served 
as a marker of mast cell degranulation, was significant in congenic control 
mouse hearts, it was negligible in the mast cell-deficient mice (Figure 3.10A). 
This, taken with the fact that renin-positive mast cells were only observed in
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congenic control heart sections (Figure 3.8), confirmed the mast cell-deficient 
phenotype of the c-kit-null mice. Substantially higher levels of renin activity 
and NE were observed in the coronary effluent of congenic control, as 
compared to mast cell-deficient mouse hearts subjected to ischemia- 
reperfusion (Figures 3.9 and 3.1 OC). The critical role of mast cell-derived 
renin was highlighted by the fact that treatment of congenic control mouse 
hearts with the renin specific inhibitor BILA2157, exhibited minimal NE 
overflow similar to that observed in c-kit-null mice (Figure 3.10D). In the 
absence of mast cells, BILA2157 exerted no further inhibition of NE overflow. 
Therefore, it is proposed that mast cells represent the major source of cardiac 
renin which is paramount in local renin-angiotensin system activation and 
ultimately drives excessive NE release.
In summary, the hypothesis that renin release from cardiac mast cells 
is a pivotal trigger for renin-angiotensin system activation leading to excessive 
release of NE has been substantiated. Represented schematically in Figure 
3.12, it is proposed that mast cell degranulation, as occurs in myocardial 
ischemia, releases active renin capable of cleaving interstitial 
angiotensinogen to form ANG I. Cardiac ACE drives the local formation of 
ANG II from ANG I, which then activates ATi-receptors on cSNE. The 
subsequent stimulation of NHE activity increases intraneuronal Na^ and 
thereby exacerbates carrier-mediated NE release (Levi and Smith, 2000). It is 
plausible therefore, that mast cell-derived renin may be a useful therapeutic 
target for cardiac dysfunctions associated with adrenergic hyperactivity, such 
as arrhythmias, sudden cardiac death, myocardial ischemia and infarction, 
cardiac hypertrophy and congestive heart failure (Julius, 1993; Dart and Du,
9 3
Thesis Christina J. Mackins
1993; Kübler and Strasser, 1994; Benedict et a!., 1996; Selwyn and 
Braunwald, 2001).
MAST CELL
Angiotensinogen
ANG II
MYOCARDIAL ISCHEMIA
renin 
ANG I
©
Interstitium
( \ 
Sympathetic nerve ending
AJip / '  ' ®  S ' ...
f T Free '^fia
Figure 3.12 A schematic representation of the substantiated hypothesis.
Myocardial ischemia induced degranulation of renin-containing mast cells 
activates a local renin-angiotensin cascade, thereby exacerbating carrier- 
mediated NE release from cardiac sympathetic nerve endings. Abbreviations: 
ACE, angiotensin-converting enzyme; ATiR, angiotensin (type 1) receptor; 
NET, NE transporter; NHE, Na^/H^ exchanger.
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4. Signaling mechanisms o f  the histamine H3 receptor
4.1 Introduction
Histamine H3 receptors were first identified as auto-inhibitory receptors 
on histaminergic neurons in the brain (Arrang et al., 1983). Since then, the 
Hs-receptor has also been shown to inhibit presynaptically the release of a 
number of other neurotransmitters (i.e. acting as a hetero-inhibitory receptor) 
in the peripheral as well as central nervous system (Hill et al., 1997; Levi and 
Smith, 2000). Our laboratory has previously demonstrated that sympathetic 
nerve endings of guinea pig and human heart express Hs-receptors, which 
upon activation inhibit exocytotic NE release (Endou et al., 1994; Imamura et 
al., 1995). Although normally quiescent, Hs-receptors become activated by 
endogenous histamine released from mast cells during myocardial ischemia 
(Hatta et al., 1997; Imamura et al., 1994). Since excess NE release 
associated with myocardial ischemia can trigger severe arrhythmias and 
sudden cardiac death (Benedict et al., 1996; Dart and Du, 1993; Selwyn and 
Braunwald, 2001), Hs-receptors play an important cardioprotective role (Levi 
and Smith, 2000).
Hs-mediated inhibition of exocytotic NE release from cardiac 
sympathetic nerve endings is associated with a marked decrease in Ca^  ^
entry upon depolarization (Silver et al., 2002). This effect is likely mediated by 
an inhibition of Ca^  ^ entry via N-type Ca^  ^ channels, as the specific N-type 
Ca^  ^ channel blocker co-conotoxin (Sher et al., 1991) decreases both Ca^  ^
entry and NE exocytosis similar to the specific Hs-receptor agonist imetit 
(Garbarg et al., 1992; Silver et al., 2002). Furthermore, Hs-mediated inhibition
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of N-type current has been claimed to occur in histaminergic neurons of 
the rat brain (Takeshita et al., 1998).
Little is currently known about the intracellular signal transduction 
pathways coupled to Hs-receptors (Hill et al., 1997). Cardiac Hs-receptors are 
most likely Gj/Go coupled. A previous study in our laboratory demonstrated 
that Hs-induced inhibition of NE release in isolated guinea pig atria was 
pertussis toxin-sensitive G/Go coupled (Endou et al., 1994). Also, transfection 
of the cloned Hs-receptor into a variety of cell lines confers an ability to inhibit 
forskolin-stimulated cAMP formation in response to histamine (Lovenberg et 
al., 1999).
The mechanism by which Hs-receptors attenuate NE exocytosis was 
investigated in a neuroblastoma cell line considered to be an optimal model of 
sympathetic nerve endings (Vaughan et al., 1995): SH-SY5Y cells stably 
transfected with the Hs-receptor (SH-SY5Y-Hs). cAMP-dependent 
phosphorylation of N-type Ca^ "" channels is known to increase their activity 
(Ahlijanian et al., 1991; Hell et al., 1995; Catterall, 2000). Accordingly, the 
aim of this study was to explore the possibility that Hs-receptors minimize 
neuronal N-type Ca '^" influx and subsequently NE exocytosis by reducing 
cAMP levels.
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4.2 Methods
Preparation of guinea-pig and porcine cardiac synaptosomes.
This procedure was conducted by Dr. Nahid Seyedi. Hearts from male 
Hartley guinea-pigs were isolated and perfused as described in Chapter 3. 
Normothermic 10-min global ischemia was induced by complete cessation of 
coronary perfusion, followed by reperfusion. In vivo porcine coronary 
occlusion, by ligation of a coronary artery branch, was carried out in the 
laboratory of Dr Paul Heerdt (Dept, of Anaesthesiology, Weill Medical 
College). Synaptosomes were prepared from control and ischemic guinea-pig 
hearts and from control and ischemic regions of porcine heart as described in 
Chapter 2.
Western blotting. This was carried out as described in Chapter 2. 
The Hs-receptor antibody was kindly supplied by Dr. P. Chazot (University of 
Durham, UK).
SH-SYSY-Hs cells. The human neuroblastoma cell line stably 
transfected with the Hs-receptor (SH-SY5Y-Hs) was kindly supplied by Dr. T. 
W. Lovenberg (R. W. Johnson Pharmaceutical Research Institute, CA). Cells 
were maintained in a 1:1 ratio of Eagle's and Ham's F-12 minimal essential 
medium mixture, supplemented with 10% fetal bovine serum, 2 mM L- 
glutamine, 450 pg/ml geneticin, 50 units/ml penicillin, and 50 pg/ml 
streptomycin at 37°C, 5% CO2 . Cells were grown to confluence in 6 -, 24-, or 
96-well plates for PKA activity, [^H]NE release experiments, and cAMP assay, 
respectively, or for 4 to 5 days on 22-mm^ standard glass coverslips (no. 1 ) for
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measurements. Cell culture media and supplements were purchased 
from Mediatech (Herndon, VA).
[^H]NE Release Assay. The [^H]NE release method was adapted from 
that described by Murphy et al. The culture medium was removed and cells 
were washed once with HEPES-buffered Na^ Ringer's solution (140 mM NaCI, 
5 mM KCI, 10 mM HEPES, 2 mM CaCb, 1 mM MgCL, pH 7.4 containing 0.2 
mM pargyline), and then incubated in 230 pl/well of Na  ^ Ringer's buffer 
containing 50 nM [^H]NE for 60 min at 37°C. This was followed by three 
washes with 450 pl/well Na’" Ringer's buffer (containing 1 pM desipramine, to 
prevent spontaneous carrier-mediated release). Release buffer (Na"" Ringer's 
buffer with 100 mM K’", adjusted to maintain osmolarity) was then added to 
each well (450 pl/well) for 5 min at room temperature. A 300-pl aliquot of the 
supernatant was taken from each well for counting, and the remaining solution 
was discarded. 0.3% Triton X-100 was then added to the cells (450 pl/well) 
for 30 min, and 300 pi of lysate was taken for counting. Samples taken for 
counting were each added to 4 ml of Bio-Safe II scintillation cocktail and 
counted on a Beckman Coulter LS6000 scintillation counter. For drug 
experiments, after the three washes cells were incubated in 450 pi of Na"" 
Ringer's buffer containing the given drug for 5 min at 37°C, followed by 
release as described above. [^H]NE release was expressed as a percentage 
of the total [^H]NE content.
cAMP Assay. SH-SY5Y-Hs cells were grown to confluence in 96-well 
plates. After a 20-min treatment with the cAMP phosphodiesterase inhibitor 3- 
isobutyl-1 -methylxanthine (IBMX; 2 mM), the cells were incubated for 5 min
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with or without the Hs-receptor agonist imetit (100 nM), either alone or in 
combination with the Hs-receptor antagonist clobenpropit (CBP; 25 nM), still in 
the presence of I BMX. Cells were incubated with CBP for 5 min before the 
addition of imetit. Intracellular cAMP levels were then stimulated by either 
forskolin (10 pM) for 20 min, or high K"" (100 mM) for 5 min. The cells were 
immediately aspirated, then lysed and the intracellular cAMP levels 
determined using a cAMP Biotrak EIA kit (Amersham Biosciences Inc., 
Piscataway, NJ) following the manufacturer's protocol.
Detection of PKA Activation. Confluent SH-SY5Y-Hs cells were 
washed with serum-free medium and then maintained in Eagle's minimal 
essential medium/Ham's F-12 with 0.1% bovine serum albumin for 48 h. PKA 
phosphorylation (i.e., an indication of PKA activation) was elicited by 
incubating SH-SY5Y-Hs cells with forskolin ( 1 0  pM) or K'" ( 1 0 0  mM) for 5 min, 
in the absence or presence of imetit (100 nM), either with or without CBP (25 
nM). SH-SY5 Y-H3 cells were lysed (lysis buffer composition: 1 % Triton X -1 0 0 , 
0.5% deoxycholic acid, 50 mM Tris-HCI, 0.1% SOS, 1 mM EDTA, 50 mM 
NaCI). Samples of lysate (10 pg/lane) were prepared with 5x Tris-glycine SOS 
sample buffer and boiled for 5 min before separation on 8 % Tris-glycine SDS- 
polyacrylamide minigels (Gradipore, NSW, Australia). Western blotting was 
conducted as described in Chapter 2. p-PKAa antibody (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) was used as primary antibody. In the 
immunoblot, phosphorylated PKA was visualized, as expected, as a single 
band at 54 kDa (Tasken et al., 1995). Bands were analyzed by densitometry 
using NIH Image, version 1.61.
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[Ca^^i Measurements. These were carried out as described in 
Chapter 3.
PGE2 Assay. Guinea-pig synaptosomes prepared from control hearts 
were incubated with imetit (100 nM) or A23187 (10 pM) for 10 min. Where the 
Hs-receptor antagonist clobenpropit (CBP; 50 nM) was used, samples were 
incubated with CBP for 10 min before incubation with imetit or A23187. 
Controls were incubated for an equivalent length of time without drugs. 
Following low-speed centrifugation synaptosomal supernatants were assayed 
for PGE2 release using a PGE2 EIA kit (Cayman Chemical, Ann Arbor, Ml), 
following the manufacturer’s protocol.
Drugs and Chemicals. Desipramine, 3-isobutyl-1-methylxanthine, 
imetit dihydrobromide, clobenpropit dihydrobromide, forskolin, ionomycin, 
pargyline, and Triton X-100 were purchased from Sigma-Aldrich (St. Louis, 
MO). Myristoylated PKI(14-22) amide was purchased from BIOMOL Research 
Laboratories (Plymouth Meeting, PA). pH]NE (28.0 Ci/mmol) was purchased 
from Amersham Biosciences, Inc. Fura-2 AM was obtained from Molecular 
Probes (Eugene, OR).
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4.3 Results
Detection of Hs-receptor protein in cardiac sympathetic nerve endings
Western blot analysis confirmed the presence of Hs-receptor protein in 
sympathetic nerve endings isolated from porcine and guinea-pig hearts 
(Figure 4.1). An immunoreactive band observed at -8 4  kDa was consistent 
with that seen in SH-SY5Y-Hs cells run in parallel as a positive control. In 
synaptosomes isolated from an area of porcine heart made ischemic by 
coronary artery occlusion, there appeared to be an increase in abundance of 
Hs-receptor protein as compared with synaptosomes isolated from a non­
ischemic area. Furthermore, the same tendency was observed in 
synaptosomes isolated from guinea-pig hearts subjected to 1 0 -min stop-flow 
global ischemia (Figure 4.1). These data suggest that myocardial ischemia is 
associated with a marked increase in neuronal Hs-receptor protein 
expression.
Hs-receptor-mediated attenuation of NE exocytosis is associated with a 
decrease in intracellular cAMP
The adenylyl cyclase activator forskolin (0.1-10 pM), elicited a dose- 
dependent increase (-10-35%) in NE release from SH-SY5Y-Hs cells (Figure 
4.2A). Forskolin (10 pM) was also associated with a large increase in 
intracellular cAMP (Figure 4.2D). The specific Hs-receptor agonist imetit (100 
nM) markedly attenuated the forskolin-induced increase in cAMP and NE 
release, and both these effects were inhibited by the Hs-receptor antagonist 
clobenpropit (25 nM) (Figure 4.2B and D). Similarly, imetit antagonized
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elevated intracellular cAMP levels and associated NE release elicited by K'" 
depolarization, and this was also blocked by clobenpropit (Figure 4.2C and E).
Hs-receptor-induced attenuation of NE exocytosis is mediated by a 
decrease in PKA activity
Since PKA phosphorylation is indicative of PKA activity (Erlichman et 
al., 1974), phosphorylated PKA (p-PKA) was assayed by Western blot in SFI- 
SYSY-FIs cells (Figure 4.3). Imetit (100 nM) significantly reduced the level of 
PKA phosphorylation elicited by either forskolin (10 pM; left) or K"" (100 mM; 
right). Pretreatment with clobenpropit (CBP, 25 nM) prevented the imetit- 
induced reduction of PKA activity, independently of whether PKA 
phosphorylation was enhanced by forskolin or K"" (Figure 4.3).
The Hs-receptor-mediated decrease in PKA activity leads to a reduction 
in intracellular calcium and an attenuation of NE exocytosis
To investigate whether the observed Hs-receptor-mediated decrease in 
PKA activity inhibits NE exocytosis by minimizing neuronal Ca^ "" influx, peak 
intracellular Ca^  ^([Ca^^]i) was measured in SH-SY5Y-Hs cells depolarized with 
K"", in the absence and presence of Hs-receptor activation and PKA inhibition, 
both alone and in combination. K’" depolarization (100 mM) induced a marked 
increase in peak [Ca^^i to -310 nM (Figure 4.4A). In the presence of imetit (3 
and 100 nM), peak [Ca^ j^i was reduced to -250 and -200  nM, respectively. 
Likewise, in the presence of the PKA inhibitor PKI(14-22) (0.02 and 20 nM), 
peak [Ca^ ""]; was decreased to -250 and -200 nM, respectively. However, 
upon combination, the subthreshold doses of imetit and PKI(14-22) (3 and 
0.02 nM, respectively) markedly decreased the peak [Ca^ ]^i decreased to -
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160 nM. Classical synergy was observed, in that an -30%  inhibition of K""- 
induced peak [Ca^ j^i occurred with each 3 nM imetit and 0.02 nM PKI(14-22) 
alone, upon combination at these concentrations, the inhibition of K^-induced 
peak [Ca '^']j significantly increased to -70%  (Figure 4.4B).
Hs-receptor activation leads to increased RGBs formation
To assess whether cardiac FIs-receptors are coupled to phospholipase As in 
cardiac sympathetic nerve endings, synaptosomes were prepared from 
control guinea-pig hearts and PGEs release was assayed in the supernatant 
following incubation with various drugs. The Fls-receptor agonist imetit (100 
nM) evoked a significant increase (-50% ) in PGEs formation which could be 
antagonized by preincubating the synaptosomes with clobenpropit (CBP; 50 
nM; Figure 4.5). In as much as phospholipase As is calcium-dependent 
(Kramer and Sharp, 1997), the ionophore A23187 was used as a positive 
control. A23187 (10 pM) treatment also elicited PGEs release similar to imetit, 
however this response could not be prevented by clobenpropit, as expected, 
since A23187 acts via an FIs-independent mechanism (Figure 4.5).
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Figure 4.1 Histamine Hs-receptor protein in sympathetic nerve endings 
(cSNE) isolated from guinea-pig and porcine hearts. Langendorff guinea- 
pig hearts: synaptosomes isolated from normally perfused (Control) and 10- 
min stop-flow global ischemia (Isch.). Pig heart: synaptosomes isolated from 
ischemic (Isch.) and control (Cont.) areas after coronary artery occlusion in 
vivo (20 min). cSNE (20 pg/lane) were probed with an Hs-receptor antibody. 
SH-SYSY-Hs cells (25 pg) were run as a positive control. The band indicated 
with an arrow at -8 4  kDa increases in abundance with ischemia and matches 
the glycosylated form of Hs-receptor (unglycosylated form is -4 4  kDa).
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Figure 4.2 Hs-receptor activation inhibits [^H]NE release and associated 
increase in intracellular cAMP levels elicited by forskolin or K* in SH- 
SY5Y human neuroblastoma cells transfected with the human Hs- 
receptor (SH-SY5Y-Hs). A, concentration-response curve for the forskolin- 
induced [^H]NE release. Points are means ± S.E.M. {n = 41-45). B and C, 
[^H]NE release elicited by 10 pM forskolin or 100 mM in the absence or 
presence of imetit (100 nM), either alone or in combination with clobenpropit 
(CBP, 25 nM). Columns are means ± S.E.M. {n = 16-18 and 25-29, for B and 
C, respectively). *, significantly different from control (P < 0.01 by ANOVA 
followed by post hoc Dunnett's test). D and E, increase in intracellular levels 
of cAMP in response to 10 pM forskolin or 100 mM in the absence or 
presence of imetit (100 nM), either alone or in combination with clobenpropit 
(CBP, 25 nM). Columns are means ± S.E.M. {n = 3 and 9, for D and E, 
respectively). Significantly different from control (*, P < 0.01 and **, P < 0.001 
by ANOVA followed by post hoc Dunnett's test).
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Figure 4.3 Hs-receptor activation inhibits the phosphorylation of PKA 
(i.e., PKA activation) elicited by forskolin or K* in SH-SYSY-Hs ceils.
Upper strips, representative immunoblots of SH-SYSY-Hs cell lysate probed 
with anti-phosphorylated PKA antibody (see Materials and Methods for 
details; 10 pg of protein/well). Columns (means ± S.E.M. of 6  and 12 
experiments for forskolin and K ,^ respectively) represent the level of PKA 
phosphorylation, expressed as percentage of maximal response to 10 pM 
forskolin or 100 mM K^ , in the absence or presence of imetit (100 nM), either 
alone or in combination with clobenpropit (CBP, 25 nM). *, significantly 
different from control (P < 0.01 by ANOVA followed by post hoc Dunnett's 
test).
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Figure 4.4 Hs-receptor activation and PKA inhibition act synergistically 
to attenuate the peak [Ca^*]i elicited by K* depolarization in SH-SYSY-Hs 
cells. A, peak [Ca^ "^ ]i levels elicited by depolarization with 100 mM K ,^ in the 
absence (C) or presence of imetit (3 and 100 nM) and PKI(14-22) (0.02 and 
20 nM), either alone or in combination [0.02 nM PKI(14-22) + 3 nM imetit]. 
Basal [Ca^ j^i level before K^  depolarization was 105 ± 0.32 nM (n = 1057 
cells). B, percentage of inhibition of K^-induced peak [Ca^ "^ ]i demonstrating 
synergism of action between imetit and PKI(14-22) (same data as in A). 
Columns represent means ± S.E.M. of 325 cells (Control), 72 and 205 cells 
(for 3 and 100 nM imetit, respectively), 207 and 142 cells [for 0.02 and 20 nM 
PKI(14-22), respectively], and 106 cells [for 0.02 PKI(14-22) + 3 nM imetit]. **, 
P < 0.01, from control by one-way ANOVA followed by Dunnett's test, i, P < 
0.001, from the sum of imetit + PKI(14-22) by unpaired t test.
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Figure 4.5 Hs-receptor activation generates PGE2 in guinea-pig cardiac 
synaptosomes. PGE2 release elicited by imetit (100 nM) or A23187 (10 pM) 
in the absence and presence of clobenpropit (CBP, 50 nM). Columns are 
means ± S.E.M. {n = 4). Significantly different from control (*, P < 0.05 by 
ANOVA followed by post hoc Dunnett's test).
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4.4 Discussion
Previous studies in our laboratory have established that activation of 
presynaptic Hs-receptors in isolated sympathetic nerve endings (Seyedi et al., 
1997), atrial tissue (Imamura et al., 1995) or whole intact hearts (Imamura et 
al., 1994) inhibits depolarization-induced NE exocytosis. The presence of Hs- 
receptors on sympathetic nerve endings has now been confirmed at the 
protein level (Figure 4.1). Interestingly, Hs-receptor abundance appears to be 
elevated under ischemic conditions, which may serve to amplify its 
cardioprotective role in pathophysiological states. The inhibitory action of Hs- 
receptors upon exocytotic release of NE was recently attributed to an 
associated decrease in neuronal Ca^  ^influx (Silver et al., 2002). A decreased 
PKA-mediated phosphorylation of N-type Ca^  ^channels may be responsible. 
Elevated intraneuronal cAMP is a known trigger of exocytotic NE release 
(Markstein et al., 1984; May et al., 1995). Consequently, experiments in SH- 
SY5Y-Hs cells were directed towards establishing whether an association 
exists between Hs-receptor stimulation and decreased cAMP-dependent 
phosphorylation. Such a coupling would indeed attenuate neuronal Ca^ "^  
influx and therefore NE exocytosis.
In addition to the classical adenylyl cyclase activator forskolin (de 
Souza et al., 1983), K^-induced depolarization also has the capacity to 
stimulate cAMP accumulation (Cooper et al., 1998). Accordingly, exocytosis 
was initiated in SH-SYSY-Hs cells pre-loaded with [^H]NE by either forskolin 
treatment or depolarization. In both cases, Hs-receptor stimulation 
attenuated NE exocytosis (Figures 4.2B and C). Likewise, intracellular cAMP
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levels were also attenuated by Hs-receptor activation (Figures 4.2D and E), 
consistent with previous studies (Lovenberg et al., 1999). Thus, cAMP is 
clearly a potential candidate for Hs-receptor signaling. In parallel experiments 
using guinea-pig cardiac synaptosomes, forskolin-induced NE exocytosis 
could be attenuated by Hs-receptor activation, whereas 8 -bromo-cAMP- 
induced exocytosis was unaffected (Seyedi et al., 2005). Given that 8 -bromo- 
cAMP is a membrane permeant form of cAMP, these data suggest that 
adenylate cyclase rather than cAMP, is the key initial signaling step 
downstream of Hs-receptor activation, ultimately responsible for attenuating 
NE exocytosis.
Gi/o-coupled receptors inhibit adenylyl cyclase (Neves et al., 2002), it 
seems likely therefore that Hs-receptors are Gj/o-linked. Indeed, previous work 
from our laboratory and others has suggested an involvement of Gj/o in Hs- 
receptor-mediated attenuation of NE release from guinea-pig atria (Endou et 
al., 1994) and ileum (Blandizzi et al., 2000). More recently, in guinea-pig 
cardiac synaptosomes, pretreatment with pertussis toxin was shown to 
abolish the Hs-receptor-mediated inhibition of both K"- and forskolin-evoked 
NE release (Seyedi et al., 2005).
Since Hs-receptor-mediated attenuation of NE exocytosis is associated 
with a decrease in intracellular cAMP (Figure 4.2), it is likely that there would 
also be a decrease in cAMP-dependent phosphorylation. To test this 
possibility protein kinase A (PKA) activity was assayed in SH-SYSY-Hs cells. 
Indeed, Hs-receptor activation significantly decreased PKA activity in 
response to either K^-evoked depolarization or forskolin treatment (Figure
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4.3). A specific PKA inhibitor PKI(14-22) (Glass et al., 1989) was found to 
dose-dependently attenuate NE exocytosis from guinea-pig heart 
synaptosomes. Furthermore, if subthreshold concentrations of both PKI(14- 
22) and the specific Hs-receptor agonist imetit (Garbarg et al., 1992) were 
combined, a synergistic inhibition of NE exocytosis was observed (Seyedi et 
al., 2005). Collectively, these data suggest that the decrease in adenylyl 
cyclase activity associated with Hs-receptor activation leads to decreased 
intraneuronal cAMP levels and consequently a decrease in PKA activity.
Given that cAMP-dependent phosphorylation of voltage-gated Ca^  ^
channels is known to increase their activity (Ahlijanian et al., 1991; Hell et al., 
1995; Catterall, 2000), could an Hs-receptor-mediated decrease in PKA 
activity ultimately attenuate NE exocytosis by diminishing neuronal Ca^  ^
entry? Certainly intracellular Ca^  ^ measurements in SH-SY5Y-Hs cells were 
supportive of this notion. Hs-receptor activation and PKA inhibition each 
reduced peak [Ca^ j^i in response to K'^-induced depolarization; notably, 
subthreshold concentrations of imetit and PKI(14-22) in combination 
synergistically diminished K^ -^induced peak [Ca^ ^^ ji. Previously the Hs- 
receptor-mediated decrease in Ca^  ^ entry had been ascribed to an action on 
N-type Ca^ "" channels (Silver et al., 2002). Despite N-type Ca^  ^ channels 
being the predominant voltage-gated Ca^  ^ channels involved in initiating 
sympathetic neurotransmitter release (Lipscombe et al., 1989; Zhu and Yakel,
1997), evidence in cardiac synaptosomes suggests that L-type Ca^  ^ channels 
may also contribute to exocytotic NE release and be inhibited by Hs-receptor 
activation (Seyedi et al., 2005).
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Based on SH-SYSY-Hs findings in this chapter and evidence from 
guinea-pig cardiac synaptosomes, the signaling mechanisms underlying Hs- 
receptor-attenuated NE exocytosis from cardiac sympathetic nerve endings 
have begun to be elucidated. In summary, Hs-receptor activation seems to 
result in the following sequence of events: adenylyl cyclase inhibition (most 
likely via Gj/o-coupling), decreased cAMP formation, attenuated PKA activity, 
decreased Ca^  ^ influx through voltage-gated channels and consequently 
dirhinished NE exocytosis. Whilst it is apparent that Hs-receptor activation is 
negatively coupled to neuronal Ca^  ^ influx, the cAMP-PKA pathway may not 
be the sole mechanism involved. In fact, Gjpy subunits have been shown to 
directly modulate voltage-gated Ca^‘" channels (Catterall, 2000; Herlitze et al., 
1996; Ikeda, 1996; Dolphin, 2003) and may well contribute to Hs-receptor- 
mediated inhibition of neuronal Ca^" influx. The activity of N-type Ca^ "" 
channels is known to be upregulated following phosphorylation by protein 
kinase 0  (PKC) (Zamponi et al., 1997). PKC is dependent on diacylglycerol 
(DAG) for activation. Given that DAG is a product of phosphatidylinositol 
metabolism and that Hs-receptors may be negatively coupled to 
phosphatidylinositol turnover (Cherifi et al., 1992), the subsequent diminished 
PKC activity would favor Gipy-mediated inhibition of Ca^  ^ influx and thereby 
attenuate NE exocytosis.
Gia-coupled receptors are also known to activate phospholipase A2 
(PLA2 ) (Burke et al., 1997; Felder et al., 1991; Hunt et al., 1994). PLA2 
catalyzes the first step in the formation of arachidonic acid, the precursor of 
various eicosanoids (leukotrienes and prostaglandins). Others have utilized 
this coupling to PLA2 to ascertain Hs-receptor expression in transfected cell
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lines (Morisset et al., 2 0 0 0 ). PGE2 , one of the many products of the 
arachidonic acid cascade, was assayed in guinea-pig cardiac synaptosomal 
supernatants and was found to be enhanced by Hs-receptor activation (Figure 
4.5). Like Hs-receptors, EP3 receptors are also Gj-coupled and therefore are 
likely to inhibit voltage-gated Ca^ "" channels via their py subunit. Indeed, PGE2 
has been shown to inhibit NE release from sympathetic nerves by stimulating 
presynaptic EP3 receptors (Boehm and Kubista, 2002; Molderings et al.,
1998).
Figure 4.6 summarizes the signaling pathways implicated in the H3- 
receptor-mediated attenuation of exocytotic NE release from cardiac 
sympathetic nerve endings. Elucidation of these transductional mechanisms 
is crucial in understanding pathophysiological states such as myocardial 
ischemia and congestive heart failure, which are characterized by enhanced 
NE exocytosis.
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Ca2+
Ca2+
cAMP 
Pf—PKA*^
Ca2+ 4
NE Exocytosis
Figure 4.6 Potential signaling pathways involved in the Hs-receptor- 
mediated attenuation of NE exocytosis in cardiac sympathetic nerve 
endings. Abbreviations: AA, arachidonic acid; COX, cyclooxygenase; P, 
phosphorylation; PL, phospholipids.
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5. General Discussion
The underlying theme of this thesis research project was to investigate 
the modulation of NE release by endogenous mediators in myocardial 
ischemia. Given that a strong correlation exists between excessive NE 
release and the incidence of severe arrhythmias, cardiac dysfunction and 
sudden cardiac death (Schomig et al., 1995; Airaksinen, 1999; Esier and 
Kaye, 2000), an understanding of the factors which influence NE release is 
fundamental to the development of novel cardioprotective therapies.
To summarize, the main findings of this thesis are as follows:
>  Mast cells represent a novel source of cardiac renin.
>  Mast cells release active renin and are capable of re-synthesis.
>  Mast cells are located in close proximity to cardiac nerves.
> ATi-receptors on cSNE are positively coupled to carrier-mediated NE 
via the neuronal NHE.
>  Ischemia-induced mast cell degranulation releases significant levels of 
renin activity into the coronary effluent.
>  Mast-cell-derived renin has the capacity to trigger the cardiac renin- 
angiotensin cascade, leading to local ANG II formation, enhanced 
carrier-mediated NE release and arrhythmic cardiac dysfunction.
>  Histamine Hs-receptor signaling involves an attenuation of PKA activity, 
which decreases Ca^ "" influx through voltage-gated channels and 
consequently diminishes NE exocytosis.
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This work focuses primarily on angiotensin II, found to be elevated in 
the ischemic heart (Jalowy et al., 1999), and which is known to enhance NE 
release from cardiac sympathetic nerve endings (Seyedi et al., 1997; Reid et 
al., 2004). It is generally well accepted that a cardiac renin-angiotensin 
system exists (Danser et al., 1999; Postal and Baker, 1999). However, the 
origin of cardiac renin remains controversial. Evidence prior to this study was 
merely suggestive and limited to non-intact tissue. Renin mRNA and protein 
had been detected in cultured canine myocytes (Barlucchi et al., 2001), and 
renin mRNA had been reported in fibroblasts, endothelial and coronary 
vascular smooth muscle cells (Postal and Baker, 1999; Bader et al., 2001;
Endo-Mochizuki et al., 1995). Indeed, renin mRNA expression was found to
/
be elevated in the left ventricle of patients with heart disease (old myocardial 
infarctions, acute myocardial infarctions, and hypertrophic cardiomyopathy) 
(Endo-Mochizuki et al., 1995). In rats, an increased expression of renin 
mRNA was observed in the border zone of infarcted left ventricle (Passier et 
al., 1996). The data presented herein are the first to demonstrate that mast 
cells are a source of cardiac renin. A recent study considered the 
physiological role of cardiac mast cells, reporting small differences between 
mast cell deficient and mast cell competent rats which varied with age 
(Kennedy et al., 2005). However, the data presented in Chapter 3 suggest 
that mast cell degranulation, as occurs in ischemia, is the critical event 
responsible for triggering activation of the cardiac renin-angiotensin system. 
Therefore, mast cell renin is unlikely to play a significant role under normal 
physiological conditions. Most importantly, this study reveals that activation of 
the cardiac renin-angiotensin system by mast cell-derived renin has the
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capacity to exacerbate NE release and thereby worsen cardiac dysfunction 
and arrhythmias.
These studies have only considered the acute effects of cardiac mast 
cell-derived renin upon NE release and associated arrhythmias in ischemia. 
However, independent studies have demonstrated mast cell accumulation 
and elevation in renin mRNA expression around the necrotic region in the 
days following myocardial infarction (Engels et al., 1995; Frangogiannis and 
Entman, 2006; Passier et al., 1996). Therefore, it is tempting to speculate 
that mast cell derived-renin is ultimately responsible for angiotensin li­
med iated hypertrophic and profibrotic actions in the heart (Postal, 2000; 
Bader, 2002). Indeed, both mast cells (Frangogiannis and Entman, 2006) and 
local angiotensin II (Sun et al., 2001) are implicated in post-infarction 
myocardial healing and remodeling processes. Accordingly, angiotensin- 
converting enzyme (ACE) inhibitors have been consistently shown to 
decrease remodeling in animal models of myocardial infarction and chronic 
pressure overload (Sutton and Sharpe, 2000) and more recent work has 
shown ATi-receptor antagonism to be equally effective (Patten et al., 2003). 
Furthermore, in a murine model of heart failure it has been shown that mast 
cell-deficient mice (same strain as used in Chapter 3) and mast cell-stabilized 
normal mice are more resistant to the development of heart failure (Hara et 
a l.,2 0 0 2 ).
Most reports claiming mast cell involvement in the development of 
heart failure focus on chymase (Hara et al., 2002; Matsumoto et al., 2003; 
Stewart, Jr. et al., 2003; Palladini et al., 2003), a serine protease stored in the
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cytoplasmic granules of mast cells which is capable of converting angiotensin 
I to angiotensin II, independent of ACE (Urata et al., 1990). The relative 
contribution of ACE and chymase to cardiac angiotensin II formation is 
constantly debated; the current consensus is that in vivo at least, the local 
production of angiotensin II in the human heart appears to be regulated by 
ACE rather than by chymase (de Lannoy et al., 2001; Kokkonen et al., 2003). 
However, it was recently shown that chymase-specific inhibition in a canine 
model of heart failure decreased cardiac angiotensin II levels and improved 
left ventricular dysfunction (Matsumoto et al., 2003). In any event, release of 
renin from cardiac mast cells has the capacity to support either chymase- or 
ACE-dependent formation of ANG II from ANG I. Thus, it is conceivable that 
mast cell renin, rather than chymase, may be the pivotal factor in conditions 
associated with increased mast cell number and elevated cardiac angiotensin 
II, as occurs in the progression of heart failure.
It seems paradoxical that cardiac mast cells should play a role in 
exacerbating the NE.release associated with myocardial ischemia, since they 
are also a source of histamine, which acting via histamine Hs-receptors offers 
cardioprotection by inhibiting NE release (Levi and Smith, 2000). Histamine 
Hs-receptor activation essentially counteracts the action of angiotensin II. 
Therefore, the magnitude of NE release is governed by Hs-receptor vs. ATi- 
receptor activation. With this in mind, whilst mast cell stabilization might 
initially seem an attractive approach to ameliorate the excessive NE release 
associated with myocardial ischemia, a superior approach would be to 
pharmacologically inhibit cardiac renin, ACE or the ATi-receptor, particularly
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with the knowledge that Hs-receptor abundance on cardiac sympathetic nerve 
endings is increased following ischemia.
To fully exploit the cardioprotective potential of the histamine Hs- 
receptor, the signal transduction pathways of this receptor must be 
determined. Our laboratory previously ascribed the Hs-receptor-mediated 
inhibition of carrier-mediated NE release to a direct negative coupling with the 
neuronal NHE (Silver et al., 2001). The data presented in Chapter 4 begin to 
elucidate the signaling mechanisms responsible for Hs-receptor-mediated 
inhibition of exocytotic NE release. Indeed, Hs-receptor activation results in 
the following sequence of events: adenylyl cyclase inhibition (most likely via 
Gi/o-coupling), decreased cAMP formation, attenuated PKA activity, decreased 
Ca^  ^ influx through voltage-gated channels and consequently diminished NE 
exocytosis.
Finally, these studies have revealed a paradoxical role of mast cells as 
a source of both cardiac renin and histamine. Since minimizing NE release is 
protective in myocardial ischemia, novel therapeutic strategies should be 
directed towards inhibition of the cardiac renin-angiotensin system whilst 
simultaneously exploiting Hs-receptor signaling mechanisms.
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6. Future Directions
As with any research project there are aspects which merit further 
investigation, while new perspectives have developed and points of limitation 
have been recognized.
Initial studies confirming the presence of active renin in mast cells 
utilized HMC-1 cells, a neoplastic cell line obtained from from a patient with 
mast cell leukemia (Nilsson et al., 1994). True of any cultured cell line, HMC- 
1 may differ from native mast cells, therefore it is desirable to conduct the 
same confirmatory experiments (RT-PCR, Western blot, renin activity) in 
native cardiac mast cells. In collaboration with Dr. R. B. Silver’s laboratory, a 
mast cell isolation procedure has been established which utilizes MACS 
MicroBeads (Miltenyi Biotech, CA), superparamagnetic particles coupled to 
highly specific monoclonal antibodies. This technology allows cells 
expressing the mast cell-specific, high-affinity IgE receptor, FcsRI to be 
magnetically targeted and purified. Furthermore, this procedure will also 
enable sequencing of native mast cell renin, to identify whether or not it 
represents a novel renin isoform.
In the guinea-pig stop-flow global ischemia model, full advantage was 
taken of the fact that coronary spillover of ANG l-forming activity and NE, as 
well as duration of arrhythmias, could all be assessed from the same animal. 
This revealed the functional significance of cardiac mast cell renin in 
arrhythmogenesis. However, a limitation of the mouse stop-flow global 
ischemia model was the absence of arrythmias in all mouse hearts tested. 
Clearly the ability to monitior incidence and duration of arrhythmias is
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important as it is a direct indicator of cardiac ischemic dysfunction. The 
possibility of extending the stop-flow ischemic period was explored. Indeed, 
arrhythmias could be induced with -4 5  min stop-flow. However, the absence 
of a positive correlation between NE release and duration of VTA/F was 
suggestive of unregulated NE release, most likely due to tissue death. 
Accordingly, experiments will be directed towards an alternative ischemic 
mouse model in which normothermic ischemia is induced by 2 0  min perfusion 
with an anoxic solution (glucose-free buffer containing the reducing agent 
sodium dithionite and equilibrated with 95% N2 and 5% CO2 ). This model is 
known to trigger carrier-mediated NE release and generates arrhythmias, as 
previously demonstrated in our laboratory (Koyama et al., 2003b). In contrast 
to the stop-flow-induced ischemia model, the flow will be continuous 
throughout the duration of the experiment. Therefore, ANG l-forming activity 
and NE will need to be assayed not only during reperfusion but also during 
the anoxic period. In fact, an additional benefit of this anoxic model is that it 
will enable time course profiles of ANG l-forming activity, NE overflow and 
VTA/F occurence to be constructed, providing further insight as to the 
sequence of events which occur during and following ischemia. Hopefully this 
protocol will provide further compelling evidence from the mast cell-deficient 
and congenic control mice regarding the importance of mast cell-derived renin 
in myocardial ischemia.
An obvious and exciting concept arising from the discovery that cardiac 
mast cells are a source of renin is the possibility that mast cells in other 
tissues throughout the body may also be renin-positive. Although this cannot 
be assumed, since mast cell populations are highly heterogenous (Barrett and
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Metcalfe, 1984), it is possible that mast cell degranulation may lead to local 
renin-angiotensin system activation in the respiratory system, for example. 
Indeed, in addition to its classical vasoconstrictor action, angiotensin II has 
more recently been implicated in inflammatory responses (Suzuki et al., 
2003).
Likely candidates responsible for mast cell degranulation during 
myocardial ischemia are C5a, adenosine and reactive oxygen species (Kruger 
et al., 1990; Frangogiannis et al., 1998 and 2002). Evidence for the capability 
of any of these agents to induce the release of active renin from a cultured 
mast cell line such as HMC-1 would be novel and provide a potential 
mechanism for the initiation of mast cell degranulation in ischemia.
In terms of continuing to elucidate the signaling mechanisms 
responsible for Hs-receptor-mediated inhibition of NE exocytosis, it is 
important to next determine the extent to which Gjpy plays a role. In addition to 
decreasing adenylyl cyclase activity (Taussig et al., 1993), Gipy is also known 
to directly inhibit Ca "^' entry via voltage-gated calcium channels (Catterall, 
2000; Herlitze et al., 1996; Ikeda, 1996). In fact, the Gipy subunit is implicated 
not only with the Hs-receptor directly, but also indirectly via the EPs-receptor, 
to which the Hs-receptor is thought to be positively coupled through 
phospholipase As activation (see Figure 4.6). Our laboratory has been 
supplied with the (3y scavenging (3ARK1-(495-689) minigene (Dickenson and 
Hill, 1998; Koch et al., 1994) by Dr. R. J. Lefkowitz (Duke University Medical 
Center, NO). By assessing the effect of (3ARK1-(495-689) expression in SH- 
SY5Y-Hs cells on Hs-receptor-mediated responses (jcAMP, |PKA activation.
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|Ca2+ influx and J,NE exocytosis), it should be possible to assess the relative 
contribution of G\a and Gipy.
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